Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression


Acetyl-L-carnitine (ALCAR) contains carnitine and acetyl moieties, both of which have neurobiological properties. Carnitine is important in the β-oxidation of fatty acids and the acetyl moiety can be used to maintain acetyl-CoA levels. Other reported neurobiological effects of ALCAR include modulation of: (1) brain energy and phospholipid metabolism; (2) cellular macromolecules, including neurotrophic factors and neurohormones; (3) synaptic morphology; and (4) synaptic transmission of multiple neurotransmitters. Potential molecular mechanisms of ALCAR activity include: (1) acetylation of -NH2 and -OH functional groups in amino acids and N terminal amino acids in peptides and proteins resulting in modification of their structure, dynamics, function and turnover; and (2) acting as a molecular chaperone to larger molecules resulting in a change in the structure, molecular dynamics, and function of the larger molecule. ALCAR is reported in double-blind controlled studies to have beneficial effects in major depressive disorders and Alzheimer's disease (AD), both of which are highly prevalent in the geriatric population.



Carnitine (3-hydroxy-4-N-trimethylammoniobutanoate) (Figure 1) is present in biological cells and tissues in relatively high concentrations as either free carnitine or as acylcarnitines including acetyl-L-carnitine (ALCAR) (Figure 1). ALCAR induces many of its biological actions through the metabolic effects of its carnitine and acetyl moieties. Carnitine is important in the β-oxidation of fatty acids and the acetyl moiety can be used to maintain acetyl-CoA levels. In addition, the acetyl moiety of ALCAR can potentially be used to acetylate -NH2 and -OH functional groups in amino acids such as lysine, serine, threonine, tyrosine and N terminal amino acids in peptides and proteins, and possibly modify their structure, function, and turnover. ALCAR also has the potential to act as a molecular chaperone and interact with large molecules such as proteins and membrane lipids and change the conformation of the larger molecules and possibly alter their functional activity. The biological roles of ALCAR as a molecular chaperone and as an acetylating agent need more intense investigation.

Figure 1

Chemical structures of carnitine and acetyl-L-carnitine.

Carnitine metabolism

Carnitine, a quaternary amine, is synthesized in vivo from lysine and methionine mainly in liver, kidney, and muscle with body stores mostly in skeletal and cardiac muscle.1 Exogenous carnitine (predominantly from meat and dairy products) is the source for about 75% of the body carnitines with an average non-vegetarian diet providing about 100–300 mg carnitine daily. Carnitine is absorbed readily from the GI tract by passive and active transport mechanisms. The liver receives carnitine via the portal system and subsequently releases it to the systemic circulation. Carnitine is taken up into cells by a stereospecific transport system resulting in a 10–100 fold gradient between intra and extracellular concentrations.2 Carnitine, a small, water-soluble molecule, readily diffuses through the renal glomerulus and 95% is reabsorbed to prevent renal loss.2

ALCAR metabolism

Acylcarnitines are synthesized by carnitine acyltransferases from acylCoA and carnitine. Carnitine induces fatty acid β-oxidation in the liver3, 4 and acylcarnitines are substrates for oxidation processes in mitochondria.5 A group of different acyltransferases catalyzes the formation of short-chain, medium-chain and long-chain acylcarnitines. The enzyme for short-chain acyl groups, carnitine acetyltransferase (MW approx. 70 kDa),6, 7 is located on the inner surface of the inner mitochondrial membrane (see Figure 2) and is also present in peroxisomes and microsomes.8 Carnitine acetyltransferase has a broad spectrum of substrates with maximal velocity for proprionylCoA followed by acetylCoA and butyrylCoA.9

Figure 2

Schematic of the role of mitochondrial carnitine and ALCAR in shuttling free and acyl carnitines across the inner mitochondrial membrane. CPT, carnitine palmitoyl transferase; CAT, carnitine acetyltransferase.

ALCAR pharmacokinetics and brain uptake

ALCAR levels increase rapidly after i.v. administration (500 mg) to healthy volunteers declining to baseline after 12 h; carnitine levels increase more slowly, reach a peak in 30–60 min, and decline to baseline within 24 h.10 The measurements of mean renal clearance for both suggest saturable tubular reabsorption processes.

Parnetti et al11 studied the pharmacokinetics of oral and i.v. ALCAR administered to patients with senile dementia in a multiple dose regimen. Following i.v. bolus injection of 30 mg kg−1, plasma concentrations showed a biphasic curve with t½ of 0.073 h and 1.73 h, respectively. Oral treatment with 1.5 g daily for 50 days significantly increased both plasma and CSF ALCAR concentrations, suggesting that ALCAR penetrates the blood–brain barrier easily. ALCAR does not interact with either albumin or plasma proteins in rats, dogs, and humans.12

Kuratsune et al13 using 11C PET reported relatively high uptake of 11C labeled acetyl groups of ALCAR into brain of rhesus monkeys compared with 11C labeled N-methyl groups of either ALCAR or carnitine. This uptake was suppressed by i.v. administration of glucose. The authors suggested that endogenous serum acetyl-L-carnitine may have a role in transporting acetyl moieties into the brain, especially under conditions of metabolic stress.

Metabolic effects of ALCAR

Energy metabolism

Studies in humans and animals suggest ALCAR has a favorable role in restoring cerebral energy metabolism. First, ALCAR modulates glucose metabolism and stimulates glycogen synthesis in rats.14 Second, ALCAR increases plasma levels of adenosine and ATP,15 with the rise in adenosine levels preceding the rise in ATP. Third, ALCAR restores ammonia-induced depletion of brain energy stores in Sparse-fur mice which have elevated ammonia and glutamine levels.16 Fourth, ALCAR induces post-ischemic return of neurological function in a post cardiac arrest dog model via its effects on restoring aerobic brain metabolism.17 Fifth, the accumulation of carnitine and ALCAR in spermatozoa is correlated with progressive motility, suggesting that carnitine and ALCAR have importance in the maintenance of progressive motility which is dependent on efficient energy metabolism.18

The increase in adenosine levels before ATP after ALCAR administration suggests a role for ALCAR in the turnover of adenosine. Adenosine acts in a paracrine/autocrine manner to modulate cellular activity via specific membrane receptors19 and is an important mediator of cellular responses during cerebral ischemia and hypoxia.20 Adenosine, a metabolite of ATP, is produced from 5′-AMP by both cytoplasmic and ecto 5′-nucleotidases. S-adenosylhomocysteine hydrolase also produces adenosine and homocysteine by cleavage of 5′-adenosylhomocysteine, as well as using adenosine for 5′-adenosyl homocysteine synthesis. Adenosine can be converted to 5′-AMP by adenosine kinase and to inosine by adenosine deaminase. Studies in PC12 cells show that adenosine accumulates intra- and extracellularly during chronic hypoxia.21 The increase in adenosine appears to be due to a decrease in the enzymatic activities of adenosine deaminase and adenosine kinase with increases in enzymatic activities of both cytoplasmic and ecto 5′-nucleotidases. Kobayashi et al22 showed that adenosine inhibits membrane excitability in PC12 cells during hypoxia via the adenosine A2A receptors and Fredholm19 previously reported that adenosine receptors A1, A2A, A2B, and A3 were stimulated by increased levels of adenosine in the extracellular milieu during hypoxia. Therefore, ALCAR's ability to increase adenosine levels could have a protective effect in ischemia and hypoxia. ALCAR could potentially up-regulate the adenosine synthetic enzymes and/or down-regulate the degradative enzymes in order to increase adenosine levels. Whether ALCAR accomplishes this by interacting with or acetylating the enzymes is unknown.

We propose that beneficial effects of ALCAR on cerebral energy metabolism are mediated by ALCAR's role in supplying acetyl groups for the synthesis of acetyl-CoA which can enter the citric acid cycle. The acetyl groups could be supplied directly from ALCAR or indirectly through carnitine's role in β-oxidation of fatty acids (Figure 2). In addition, ALCAR's ability to increase adenosine levels could result in decreased membrane excitability which could have protective effects.

Lipid metabolism

Hoppel23 suggested possible physiological roles of carnitine including: (1) involvement in β-oxidation of long chain fatty acids in mitochondria; (2) buffering mitochondrial acylCoA/CoA levels, probably by mass action as the system is near steady state equilibrium; (3) possible scavenger system for acyl groups; thus, when acylCoA accumulates in either tissues or mitochondria, carnitine acyltransferases catalyze its conversion to CoA and vice versa; and (4) intracellular transport of acyl groups such as the transport of acyl groups from peroxisomes to mitochondria for β-oxidation. All of these mechanisms involve lipid metabolism.

Fatty acid β-oxidation occurs mainly in the mitochondrial matrix. Activated long-chain fatty acids synthesized outside the mitochondrial inner membrane do not readily transverse this membrane, and a special transport system is needed. The activated fatty acids are first conjugated to carnitine to form an acylcarnitine by a reaction catalyzed by acyltransferase I bound to the outer side of the inner mitochondrial membrane. Acylcarnitine is then shuttled across the inner mitochondrial membrane via carnitine acylcarnitine translocase. The acyl group is transferred back to CoA on the matrix side of the membrane, by a reaction catalyzed by acyltransferase II. Finally, carnitine is transferred back to the outside of the inner mitochondrial membrane via carnitine acylcarnitine translocase in exchange for an incoming acylcarnitine (see Figure 2 for a schematic of the role of carnitine and ALCAR in the mitochondria). The acyl-CoA that is formed undergoes oxidative removal of successive two-carbon units in the form of acetyl-CoA starting at the carboxyl end of the fatty acid chain. For example, palmitoyl-CoA yields eight acetyl-CoA molecules. For each molecule of acetyl-CoA formed from fatty acid β-oxidation, a molecule of FADH2 and a molecule of NADH are formed. The acetyl-CoA produced is oxidized to CO2 in the citric acid cycle producing one GTP (or ATP) molecule, three NADH molecules, and one FADH2 molecule. The FADH2 and NADH produced are oxidized in the respiratory electron transfer chain with each NADH molecule generating three ATP molecules and each FADH2 molecule generating two ATP molecules. Therefore, each acetyl-CoA molecule produced by fatty acid β-oxidation can produce 17 ATP molecules. ALCAR also is produced from acetyl-CoA and carnitine by carnitine acetyltransferase. The activity of carnitine acylcarnitine translocase is regulated by the intra-mitochondrial carnitine content; increases of intra-mitochondrial carnitine increases the activity of this enzyme.24 Under conditions of impaired energy metabolism, such as fasting or experimental diabetes, carnitine levels increase in the mitochondrial matrix24 and carnitine acylcarnitine translocase activity increases. Thus, carnitine has a pivotal role in the transport of activated fatty acids for β-oxidation.

ALCAR's modulation of membranes

ALCAR administration alters mitochondrial inner membrane protein composition of rat cerebellum25 and significantly increases glycerophosphocholine levels in 6-month-old rats but slightly decreases glycerophosphocholine levels in 24-month-old rats.26 ALCAR also increases the membrane molecular dynamics of brain microsomes and liposomes produced from rat brain microsomal lipid extracts27 and carnitine partially shares this effect with ALCAR. Butterfield and Rangachari28 showed that ALCAR increases membrane cytoskeletal protein–protein interactions, but no change in lipid order or molecular dynamics could be demonstrated. Since carnitine was reported to exert the same effect, these authors suggested that the acetyl group of ALCAR is not hydrophobic enough to direct ALCAR to the bilayer phase of the membrane. ALCAR increases membrane stability, possibly by interacting with cytoskeletal proteins and altering cell membrane dynamics in the region close to the glycerol backbone of the phospholipid bilayer; this could be relevant for the modulation of membrane function.29 Paradies et al30 reported that ALCAR treatment restored mitochondrial cardiolipin levels and the activity of the mitochondrial phosphate carrier. All these data demonstrate that ALCAR has membrane-modifying effects. Some of these biological effects of ALCAR could be due to a physical-chemical mechanism and some of the effects could be secondary to the acetylation of proteins, such as cytoskeletal proteins.

ALCAR's modulation of proteins and peptides

Acetylation of proteins

ALCAR is a potentially important biological acetylating agent which could modify protein structure and activity by acetylating -NH2 and -OH functional groups in amino acids such as lysine, serine, threonine, tyrosine and N terminal amino acids. The potential for ALCAR to participate in transacetylation reactions is understandable given the free energy of hydrolysis of the acetyl bond of several biologically important acetyl esters and ATP (Δ G° (Kcal mol−1) at pH 7.0 and 38°C): ALCAR, −8.20;31 acetylcholine, −6.99;31 acetylCoA, −8.54;31 and ATP (terminal PO4), −7.60.32, 33 Therefore, ALCAR has a higher potential for group transfer than either acetylcholine or the terminal phosphate of ATP, and ALCAR's participation in biologically important transacetylation reactions appears likely. An example is ALCAR's ability to acetylate lysine 28 of the Aβ peptide of β-amyloid (M Calvani, Sigma Tau Pharmaceuticals, personal communication). The acetylation of lysine 28 inhibits the peptide from forming a β-turn34 and the β-turn is considered essential in forming potentially toxic β-sheet aggregates of β-amyloid (Figure 3). In PC12 cells, ALCAR increases the acetylated form of microtubules which are more stable than the unacetylated forms and protects the cells against apoptosis. This stabilization effect during ‘sprouting’ of neurites in PC12 cells may facilitate neurite formation.35 In PC12 cells ALCAR (1 mM) significantly increases the levels of acetylated histone H4 and in synergism with low doses of nerve growth factor (NGF) (1 ng ml−1) up-regulates the expression of NGF1-A neuronal specific transcriptional factor. A recent study demonstrated that ALCAR can acetylate α crystallin.36 Acetylating α crystallin results in decreased glycation of α crystallin. The glycated form of α crystallin appears to contribute to cataract formation. Other proteins also could be candidates for acetylation by ALCAR with a resultant change in peptide or protein structure and function. There is strong evidence demonstrating that acetylation of lysine residues in cytochrome P450 inhibits the electrostatic interaction of P450 with NADPH-cytochrome P450 reductase.37, 38 Recent studies show that ALCAR pretreatment ameliorates (−)nicotine-induced changes in membrane phospholipid metabolism and in particular leads to decreased levels of phosphatidylethanolamine plasmalogen and increased levels of phosphatidylethanolamine (Pettegrew et al, unpublished observation). A possible explanation for this ALCAR-induced change in membrane phospholipid composition could be inhibition of cytochrome b5 (which is involved in phosphatidylethanolamine-plasmalogen synthesis) by acetylation of one or more of the six lysine residues found in cytochrome b5.39 Many transmembrane proteins which function as receptors and ion channels are anchored to the membrane in part by a charged polylysine ‘washer’ on the cytoplasmic side of the membrane. It is plausible to suggest that ALCAR could acetylate these lysines and secondarily modulate the function of the protein by: (1) changing the portion of protein exposed to the extracellular space; (2) modulating the turnover of the protein by increasing the exposure of the protein to extracellular proteases; or (3) increasing the secretion of the protein.

Figure 3

Molecular dynamics structures of Aβ (1–28) in its native and acetylated (Lys28) forms. Structures calculated for 250 ps using the Molecular Simulation Inc Discover program: cvff force field; periodic boundary conditions, in a box of water, a = 30, b = 60, c = 30 Å; in 1 fs steps, 10 Å cutoff distance.

Modulating the activity of NGF

NGF profoundly affects neuronal development and maintains neuronal differentiated states in various peripheral and central nervous system neurons. ALCAR-treated aged rats have improvement of age-related reduction in NGF-binding capacity found in hippocampus and basal forebrain areas40 and ALCAR increases choline acetyltransferase activity and NGF receptor expression in the developing rat striatum.41 Taglialatela et al42 reported that ALCAR: (1) enhances the response of PC12 cells to NGF suggesting that ALCAR may increase the response of aged neurons to neurotrophic factors within the CNS; (2) stimulates NGF receptors and neurite growth in PC12 cells;43, 44 and (3) increases NGF levels and choline acetyltransferase activity in rat CNS.45 Piovesan et al46 demonstrated that ALCAR increases choline acetyltransferase activity and NGF levels in the CNS of adult rats pretreated by total fimbria-fornix transection; these animals exhibit impairment of cholinergic activity similar to that seen during senescence. Taglialatela et al47 also reported that ALCAR improves spatial memory performance in aged rats with decreased intermediate performance associated with reduction of NGF levels in the basal forebrain, suggesting a non linear relationship between spatial memory performance and basal forebrain NGF levels. Together, these data suggest that ALCAR modulates the activity of NGF. It is not known if ALCAR's biological effects are due to its ability to acetylate one or more amino acids of NGF (eight lysine residues),48 by binding to NGF, by increasing NGF gene transcription/translation possibly by acetylation of histones or by a combination of these effects.

Modulating enzymatic activity

ALCAR induces post-ischemic return of neurological function in a post cardiac arrest dog model and this effect is suggested to be due to inhibition of post cardiac arrest oxidative injury to a variety of enzymes and other proteins.49 Gorini et al50 demonstrated that treatment with ALCAR decreased citrate synthase and glutamine dehydrogenase activities, and increased cytochrome oxidase and α-ketoglutarate dehydrogenase activities in intrasynaptic but not in non-synaptic mitochondria from rat cerebral cortex. ALCAR treatment increased the activity of acetylcholinesterase in synaptic plasma membranes from rat frontal cerebral cortex of 8-month-old rats51 and attenuated streptozotocin-induced decrease in hippocampal choline acetyltransferase activity.52 ALCAR increases particulate protein kinase C activity in the cortex both in vitro and in vivo in doses effective in improving spatial task learning in rats53 and subchronic administration of ALCAR enhances receptor-stimulated adenylate cyclase activity in young and aged rats.54 Villa and Gorini55 measured several mitochondrial enzyme activities and reported that in vivo administration of ALCAR decreased enzyme activities related to the Krebs cycle (ie, citrate synthase) mainly of synaptic mitochondria, suggesting a specific subcellular site of action, while it increased cytochrome oxidase activity of both synaptic and non-synaptic mitochondria. These data suggest that ALCAR has modulatory effects on a broad spectrum of mitochondrial and other intracellular enzymes, which can alter a number of intracellular reactions. Again, the mechanism responsible for ALCAR's action is unknown, but direct physiochemical interaction and protein acetylation are two possible mechanisms that need further study.

Most of the enzymes mentioned above, whose activity are altered by ALCAR, contain lysine amino acid residues that might be acetylated by ALCAR. Citrate synthase contains 14 lysine residues.56 When the positive charge on Lys 219 (exposed to aqueous solution on the membrane surface) of the C-terminal domain of cytochrome C oxidase is removed, the reaction rate is increased.57 αKetoglutarate dihydrogenase contains three lysines in the lipoyl domain and Lys 43 is the lysine that becomes lipoylated, located at the tip of an exposed β-turn. Acetylcholinesterase58 and choline acetyltransferase59 also contain lysines. Protein kinase C is synergistically activated by phosphatidylserine which binds to a lysine-rich cluster in the C2 domain.60 Lysine 938 of adenyl cyclase may be involved in a conformational transition subsequent to ATP binding and thus affect the conversion of ATP to cAMP.61 Many of the enzymes affected by ALCAR have lysine residues that are implicated in their activity and thus acetylation of lysine residues by ALCAR is a possible mechanism for ALCAR modulatory effects on these enzymes.

ALCAR's ability to acetylate -OH groups such as those on serine, threonine, and tyrosine could modulate protein structure and activity by removing those groups from potential phosphorylation by protein kinases. This could add another level of control over protein conformation and function with implications for disease states. For example, recent studies show the protein kinase Cdk5 is deregulated in Alzheimer's disease (AD),62 perhaps contributing to the increased phosphorylation of tau protein with subsequent aggregation of hyperphosphorylated tau into paired helical filaments. If these -OH groups could be blocked from phosphorylation, perhaps by acetylation by ALCAR, the production of paired helical filaments could be reduced.

Modulating hormonal activity

ALCAR affects the brain HPA axis and has a role in preventing pathological brain deterioration in stressful conditions.63 When administered to old rats, ALCAR improved regulation of the HPA axis and maintenance of glucocorticoid competence by the hippocampus. This was associated with improvement in acquiring passive avoidance behavior and reduced deposition of aging pigment.64 Costa et al65 studied the effect of ALCAR (20 mg kg−1 day−1 for 2 weeks) and piracetam treatment in 24 demented patients and found that ALCAR but not piracetam normalized the hyperfunctioning pituitary by lowering high cortisone and β-endorphin levels. This effect of ALCAR was associated with improved attention and verbal memory functions. ALCAR treatment attenuated the age-dependent increase of cold water swimming in rats, possibly by retarding the hippocampal glucocorticoid receptors loss needed to exert negative feedback control over HPA axis activity.66 These data suggest that ALCAR has regulatory effects on the HPA axis. De Simone and Calvani67 found that ALCAR treatment increased TSH levels in four HIV-positive subjects. ALCAR modulates melatonin secretion in both adult and old rats suggesting that ALCAR can modify noradrenergic neurotransmission and signal transduction in the pineal gland.68, 69 ALCAR added to perfused cultured hypothalamic cells and GTI-1 neuronal cells increases the pulsatile secretion of gonadotropin-releasing hormone by these cell cultures70 and prevents the decrease in plasma testosterone induced by a chronic swim test in rats.71 Krsmanovic et al72 reported increased gonadotropin release by ALCAR in a rat model attributing it to enhancement of GnRH neuronal function in the hypothalamus. Together, these data suggest that ALCAR can modulate the activity of hormonal systems and their regulating peptides.

ALCAR's modulation of gene expression

Taglialatela et al43 showed that ALCAR stimulates the production of NGF receptors in pheochromocytoma (PC12) cells and increases NGF receptor mRNA levels. ALCAR also has a neuromodulatory influence on neuronal phenotype during early embryogenesis in the chick embryo.73 ALCAR was administrated in ovo during embryonic days 1–3 and expression of cholinergic and GABAergic neuronal phenotypes was examined at day 8 using acetyltransferase and glutamic acid decarboxylase as markers. Alterations in the expression of these markers in cerebral hemispheres and diencephalon-midbrain-brainstem areas were observed following ALCAR treatment. ALCAR and butyrate were demonstrated by Pomponi and Neri74 to inhibit the cytogenetic expression of fragile X in vitro probably by acetylating and thus modifying histones regulating the chromatin complex. Pisano et al35 reported that ALCAR partially suppressed fragmentation of genomic DNA in PC12 cell culture induced to undergo apoptosis by deprivation of serum and NGF. ALCAR levels also are relatively high in the cellular nucleus and rise even higher during the earliest stages of cellular differentiation. All of these findings suggest an effect of ALCAR on gene activity which possibly could be related to acetylation of histones.

ALCAR's modulation of synaptic morphology and transmission

The developing and aging brain provides models to study the effects of various drugs on neuronal functioning. ALCAR has a neuromodulatory effect on neuronal cholinergic and GABAergic phenotypes during early embryogenesis in the chick embryo.73 In the aging rodent brain, ALCAR also has beneficial effects on receptor systems. ALCAR restores synaptic patterns, including the number of axosomatic synapses of granule cells and the number of synaptic vesicles in rat hippocampal giant synapses75 and chronic ALCAR treatment has a positive modulation on hippocampal synaptic structural dynamics, including the number of synapses, synaptic densities, and synaptic average area.76, 77 ALCAR also affects cholinergic transmission. ALCAR increases choline uptake into nerve terminals,78, 79 which would increase acetylcholine synthesis. ALCAR was shown to improve visual memory and attention in Down syndrome subjects80 suggesting that ALCAR might have cholinomimetic activity which contributed to the beneficial effect. Acetylcholinesterase activity in synaptic plasma membranes of 8-month-old rats is increased by ALCAR51 and in Sparse-fur mutant mice ALCAR treatment restores choline acetyltransferase activity levels and elevates β-NGF levels.81 ALCAR restores choline acetyltransferase activity in the hippocampus of rats with partial unilateral fimbria-fornix transection which produces degeneration of cholinergic pathways.82 Prickaerts et al83 demonstrated that chronic ALCAR administration to streptozotocin-treated rats attenuated choline acetyltransferase activity and the spatial memory impairment of these rats, and Taglialatela et al40 reported that ALCAR treatment increases choline acetyltransferase activity in the CNS system of aged rats and this was associated with increased NGF levels. ALCAR can counteract the age-dependent reduction of several CNS receptor systems, including NMDA receptors, NGF receptors, and glucocorticoid receptors84 and ALCAR prevents age-related NMDA receptor loss in hippocampus, striatum, and frontal cortex of rats.85 ALCAR releases dopamine in rat corpus striatum by a calcium-dependent exocytotic process86 and enhances acetylcholine release in the striatum and hippocampus of awake freely moving rats.87 Sershen et al88 demonstrated that ALCAR attenuates age-related changes in dopaminergic systems in rats and ALCAR, as well as carnitine, was reported to be a stereospecific neuroactive compound with cholinomimetic activity.89 ALCAR given to rats for 4 days elevates substantia nigra levels of GABA but not striatal dopamine.90 ALCAR ionophoretic administration on single neurons of the rat medullary-pontine reticular formation increases glutamate spontaneous and evoked firing and potentiated cholinergic and serotoninergic transmission, but has no effect on GABAergic and noradrenergic transmission.91 ALCAR administered subchronically enhances adenylate cyclase response to acetylcholine, norepinephrine, and dopamine in rat frontal cortex without affecting basal adenylate cyclase activity.54 ALCAR administered via microdialysis at different brain sites induces the release of amino acids, especially aspartate, glutamate and taurine in a concentration-dependent and regionally heterogenous manner92 and ALCAR lessens the reduction of taurine in old rats.88 In summary, ALCAR appears to have a neuromodulatory effect on synaptic morphology as well as on synaptic transmission in multiple neurotransmitter systems.

ALCAR's protection of brain tissue against neurotoxins

ALCAR can restore the thalamo-cortical system in rats prenatally exposed to ethanol93 and has a protective effect in rats injected i.c.v. with MPP+ solution.94 However, ALCAR did not have any normalizing effect on catecholamine concentrations, tyrosine hydroxylase, neurofilament or glial fibrillary acid protein, suggesting the ALCAR protective action could be related to energy metabolism and not to effects on dopaminergic systems. Forloni et al95 reported that ALCAR reduces the mortality in rat brain cell cultures after exposure to neurotoxic stimuli including NMDA and Aβ(25–35) peptide and ALCAR can inhibit cell apoptosis and retard DNA fragmentation and nuclear condensation in a teratocarcinoma cell line in which apoptosis was induced by serum deprivation.96 Although this last study was done in a non-brain tissue, it may indicate that ALCAR could have similar effects in CNS tissue. In general, these data suggest that ALCAR provides a protective effect against a variety of neurotoxins.

ALCAR's neuroprotection effect on aging processes and related disorders

Animal aging studies

ALCAR was reported to ameliorate the spatial memory performance of rats exposed to neonatal anoxia.97 Taglialatela et al47 reported improvement of spatial memory in aged rats could be achieved only in intermediate but not in good or poor classes of spatial learning performance. Caprioli et al98 reported that improvement could be achieved for novel but not for familiar environments. Since the improvement was not global, ALCAR might affect specific neuronal systems leading to specific types of improvement. ALCAR attenuates the decrease in hippocampal choline acetyltransferase activity following i.c.v. administration of streptozotocin which inhibits glucose utilization.52 The anti- amnesic effect of ALCAR is associated with an activating effect on protein kinase activity.53

Human AD studies

Three parallel design placebo-controlled studies of ALCAR in AD have been reported; each studied the possible effect of ALCAR vs placebo in preventing the deterioration associated with this disease over a period of 1 year.

Spangioli et al99 conducted a multi-center study of 130 patients with probable AD. Family history of dementia was not given for the patients. Sixty-three patients were randomized to ALCAR treatment (2 g daily) and 67 to placebo. The mean age for both groups was approximately 75 and 66–75% of the subjects in each group were women. Fourteen outcome measures were employed to assess function and cognitive impairment. After 1 year, both placebo and ALCAR groups deteriorated; however, the ALCAR group deteriorated significantly less than the placebo group in 13 out of 14 outcome measures. For example, with placebo treatment the mean ± SD score in Raven's matrices was reduced from 5.6 ± 3.9 to 3.8 ± 3.7 (mean delta of 1.8), and in the ALCAR group this measure was reduced from 6.7 ± 4.8 to 6.3 ± 4.7 (mean delta of 0.4), demonstrating less deterioration in the ALCAR group (P = 0.01). Similarly, the Verbal Judgement and Mental Calculation Test scores with placebo treatment were reduced from mean ± SD 25.8 ± 12.0 to 20.4 ± 14.3 (mean delta of 5.4), and for the ALCAR-treated group was reduced from 28.5 ± 14.0 to 26.8 ± 14.4 (mean delta of 1.7), showing less deterioration (P = 0.02) than the placebo group.

Pettegrew et al100 conducted a 31P-MRS double-blind, placebo-controlled study of ALCAR in 12 patients with probable AD. Five patients were treated for 1 year with placebo (one male, four females; age 64.2 ± 2.6; 13.4 ± 1.6 years of education (mean ± SEM)) and seven patients were treated for 1 year with ALCAR (3 g daily) (three males, four females, age 70.7 ± 3.3; 11.4 ± 0.9 years of education). The AD subjects were compared with 21 controls (11 males, 10 females; 70.5 ± 1.3 years; 14.8 ± 0.6 years of education). There was no significant difference in age or years of education between the ALCAR, placebo, and control groups. Two of the ALCAR and three of the placebo subjects had a family history for dementia. Apolipoprotein E (apoE) genotyping was not available at the time of the study. Alzheimer's disease and assessment scale—cognitive subscale (ADAS-Cog, patient is the information source) and Mini Mental Status (MMS) scales were used to assess the patients’ deterioration after 6 and 12 months of treatment. At entry, the MMS score of the ALCAR group was 18.4 ± 0.8, that of the placebo group was 18.0 ± 0.8, and that of the controls was 29.0 ± 0.3. The ADAS-cog score at entry was 22.1 ± 3.0 for the ALCAR group and 21.3 ± 2.7 for the placebo group. On the whole, ALCAR was found to be superior to placebo at 6 (P = 0.01) and 12 months (P = 0.01). MMS was not significantly different at 12 months from entry for the ALCAR group (P = 0.56), but the placebo group showed significant deterioration at 12 months from entry (P = 0.03). ADAS-cog was not significantly different at 6 months compared to entry for the ALCAR group (P = 0.64), but the placebo group showed a statistically significant deterioration (P = 0.01). Three of the placebo and two of the ALCAR-treated subjects had a family history of dementia. Over the 12 months of follow-up, the placebo-treated subjects with a family history of dementia had a decrease in MMS score of 1.66, compared with a mean decrease of 1.0 for the ALCAR-treated subjects (P = NS) and an increase in ADAS-Cog score of 8.3, compared with an increase of 0.16 for the ALCAR-treated subjects (P = 0.06). Therefore, even in those subjects with a family history of dementia the cognitive decline in the ALCAR-treated subjects appeared slowed compared with the placebo-treated subjects. ALCAR was found to increase brain phosphomonoester levels at 6 months compared to entry (P = 0.03) and to increase levels of ionized ends (α-ATP) at 6 months (P = 0.04) and phosphocreatine at 12 months (P = 0.005). The clinical effects of ALCAR were therefore associated with improvement in brain measures of membrane phospholipid and high-energy phosphate metabolism.

Thal et al101 conducted a multi-center study of ALCAR treatment for probable AD patients. This was a 1-year parallel randomized, placebo-controlled, double-blind study of 431 patients age 50 and above at entry, 340 completed the study. The ALCAR and placebo groups were matched for age, MMS, ADAS, and level of education at entry. ApoE genotyping was not performed on these subjects and family history of dementia was not given. Demographic data were presented for 419 subjects consisting of a group of intention to treat—last observation carried forward. Of these, 212 patients (43% male; age 71 ± 8) were randomized to placebo treatment and 207 patients (45% male; age 72 ± 7) were randomized to ALCAR treatment (3 g daily). Each treatment was given for 1 year. Outcome measures included the ADAS, MMSE, and Washington University Clinical Dementia Rating Scale (CDR). No difference was noted between the two groups as a whole. However, a group of patients below 65 years showed a trend for less deterioration with ALCAR treatment compared with placebo in ADAS-Cog scores (P = 0.11) and CDR scores (P = 0.056). With placebo treatment ADAS-Cog scores (mean ± SD) increased from 26 ± 11 to 35 ± 14 (mean delta = 9) and with ALCAR treatment this measure increased from 28 ± 11 to 35 ± 16 (mean delta = 7). This relatively younger group of patients also demonstrated an increase of CDR scores (mean ± SD) from 6.2 ± 3 to 9.5 ± 4 (mean delta = 3.2) with placebo; the CDR scores for the ALCAR-treated group increased from 6.1 ± 2 to 8 ± 4 (mean delta = 1.9), demonstrating less deterioration compared with placebo. Brooks et al102 reanalyzed the results of Thal et al101 for completers and reported that both ALCAR and placebo demonstrate the same rate of change in ADAS scores (0.68 points per month). However, multiple regression analysis of the data showed significant age × drug interaction characterized by younger subjects benefitting more from ALCAR treatment compared with older subjects. Further analysis suggested that the optimal cutoff point for ALCAR benefit may be 61 years of age.

On the whole, these studies suggest that ALCAR could have a therapeutic effect in decreasing the deterioration associated with AD. ALCAR treatment could be more beneficial in presenile AD than in senile AD. Regrettably, Thal et al101 did not report whether there was a statistically significant difference between the different centers participating in the study which could explain the lack of ALCAR superiority to placebo in the whole group of subjects.

For comparison, several studies have investigated the effects of cholinesterase inhibitors in AD. Tacrine, a cholinesterase inhibitor frequently used in the treatment of AD patients, was also reported to demonstrate positive103 as well as negative104 results in well controlled studies. In a meta analysis Qizilbash et al105 suggested that tacrine: (1) is mainly effective in reducing deterioration in the first 3 months of illness; (2) seems to have no effect on behavioral disturbances; and (3) that functional neuroanatomy seems to be not significantly affected.

Another cholinesterase inhibitor, rivastigmine, was examined by Rosler et al106 in a prospective, randomized, multi-center, double-blind, placebo-controlled, parallel group trial in which AD patients received either placebo or rivastigmine. Family history of dementia and apoE genotype data were not presented. Rivastigmine doses were increased in one of two fixed dose ranges (1–4 mg day−1 or 6–12 mg day−1) over the first 12 weeks with a subsequent assessment period of 14 weeks for a total study time of 26 weeks. Outcome measures were: (1) ADAS-Cog; (2) global function determined by clinician interview of patient and caregiver and; (3) a progressive deterioration scale based on activities of daily living with the caregiver as the information source. At the end of 26 weeks, compared with placebo, AD patients on 6–12 mg day−1 of rivastigmine had improvement in: (1) ADAS-cognitive scores (24% vs 16%, P < 0.05); (2) global function (37% vs 20%, P < 0.001); and (3) progressive deterioration scale (49% vs 39%, P = 0.04). Adverse events (mainly gastrointestinal) were reported in 23% of AD patients treated with 6–12 mg day−1 of rivastigmine, 7% treated with 1–4 mg day−1, and 7% of the patients on placebo.

A 24-week, double-blind, placebo-controlled trial of donepezil in 473 AD patients was reported by Rogers et al.107 No family history of dementia or apoE genotype data were given. Patients were randomly assigned to treatment with placebo (n = 162), 5 mg day−1 donezipil (n = 154), or 10 mg day−1 donezipil (n = 157) for 24 weeks followed by a 6-week, single-blind placebo washout. For the 10 mg day−1 donepezil group a blinded forced titration scheme was used in which subjects received 5 mg day−1 donepezil for the first week and then 10 mg day−1 for the remainder of the study. The donepezil 10 mg day−1 group (74.6 ± 0.64 years (mean ± SEM) was older than the placebo group (72.6 ± 0.6 years) (P = 0.03). Primary efficacy measures were the ADAS-cog and the Clinician's Interview Based Assessment of Change-Plus (CIBIC-plus) with the MMS, Clinical Dementia Rating Scale-Sum of the Boxes (CDR-SB), and patient-rated Quality of Life (QoL) used as secondary measures. Evaluations were at baseline, 6, 12, 18, and 24 weeks, and after 6 weeks of washout (30 weeks). Results for the ADAS-cog revealed that the placebo and donepezil groups all improved at 6 weeks followed by steady worsening in the placebo group and slight worsening in both donepezil groups compared with baseline. Compared with the placebo group, the ADAS-cog scores were significantly better for both donepezil groups at 12 weeks (5 mg day−1, P = 0.0007; 10 mg day−1, P = 0.0012), 18 weeks (5 mg day−1, P = 0.0012; 10 mg day−1, P < 0.0001), and 24 weeks (5 mg day−1, P < 0.0001; 10 mg day−1, P < 0.0001). In total, the ADAS-cog scores appear to deteriorate at a slower rate in the donepezil groups over the 24 weeks of follow-up. However, after 6 weeks of placebo washout (week 30) the values of ADAS-cog, for the placebo and two donepezil dosage groups were indistinguishable. Similar patterns of findings were observed for the MMS, CIBIC, and CDR-SB results. There were no observed differences in QoL measures among the placebo and donepezil groups at any time points. These results suggest that donepezil is primarily slowing symptoms associated with AD and not any underlying pathophysiological mechanism since after 6 weeks of placebo washout, the placebo and donepezil groups are clinically indistinguishable. Compared with the placebo group, the 10 mg day−1 donepezil group had significantly higher numbers of treatment-emergent signs and symptoms such as diarrhea (17%, P ≤ 0.05), nausea (17%, P ≤ 0.05), and vomiting (10%, P ≤ 0.05).

It is of interest that the percentage of AD patients who clinically improved on 6–12 mg day−1 of rivastigmine (24%) was very similar to the percentage who reported adverse gastrointestinal events (23%) and there was a significant difference in the number of gastrointestinal side effects between placebo and 10 mg day−1 donepezil (P ≤ 0.05). It should be pointed out that it is very difficult to conduct a double-blind trial of a cholinesterase inhibitor given the clinical side effects of these drugs, ie, the patient could know when they are on active drug because of the side effects. These and other concerns about study design of cholinesterase inhibitors have been pointed out by van Gool108 and Bayer.109

Interestingly, Farlow et al110 reported that the treatment outcome of tacrine depends on the apolipoprotein genotype and gender of the subjects with AD. And even the Thal et al101 study found that ALCAR was more beneficial in a subgroup of patients. Thus, future studies need to better define the sub-group of AD patients who could benefit from ALCAR. These data, taken together, suggest that ALCAR could have a neuroprotective effect on aging processes with more specific effects on ameliorating memory decline. It also suggests that within the context of the currently available drug therapies for AD, ALCAR may have a role in certain subgroups of AD patients, with fewer side effects compared with the anticholinesterases. Further studies also may examine the therapeutic efficacy of the combination of anticholinesterases and ALCAR in this disease.

Possible modes of action of ALCAR in AD

What is the possible mode of action of ALCAR in AD? In order to suggest possible mechanisms there is a need to demonstrate that ALCAR may either attenuate pathophysiological effects associated with this disease or augment physiological mechanisms compensating for dysfunctional processes caused by the disorder. Considering the research data presented above, we suggest that ALCAR may act at one or more of seven possible targets attenuating pathophysiological changes caused by this disorder.

Restoration of cell membranes

There is solid evidence for ALCAR's role in affecting membrane composition, molecular dynamics, and function. There also is solid evidence for a fundamental alteration in membrane phospholipid composition and metabolism in AD.111, 112, 113, 114, 115, 116, 117, 118, 119 Of considerable importance is the observation that the membrane molecular changes actually precede cognitive decline.120 In addition, there is in vivo evidence that ALCAR can reverse these membrane molecular and metabolic changes in some AD subjects.100

Restoration of synaptic function

The effects of ALCAR on synaptic functioning were presented above. There is considerable research data demonstrating dysfunctional synaptic functioning in normal aging and especially in AD. In particular, AD is associated with synaptic change and/or loss,121, 122, 123 including synaptic vesicles, recycling dysfunctions,124 and reduced synaptic proteins.125 The changes in membrane phospholipid metabolism found in AD and ALCAR's ability to restore these changes probably contribute to the effects of ALCAR on synaptic functioning in AD.

Augmentation of cholinomimetic activity

AD demonstrates a decrease in a variety of cholinergic indices including cholineacetyl transferase, acetylcholine esterase and the number of brain cholinergic neurons126 and ALCAR has a beneficial neuromodulatory effect on cholinergic neurotransmission. It is of note that some cholinomimetic agents are found to have some beneficial effect in slowing this disease process.127

Restoration of brain energy

ALCAR has a demonstrated ability to restore brain energy levels. Pettegrew et al117 demonstrated by 31P MRS a decrease in PCr levels in mildly demented AD subjects which correlated with the degree of cognitive decline. Similar PCr changes were observed in one subject 46 months prior to cognitive changes and the PCr changes correlated with measures of cognitive decline.120 Rapoport et al128 summarized more than 20 cross-sectional PET studies of brain functional activity in patients with probable AD. These studies demonstrate metabolic reductions in the neocortex showing increased severity in relation to the dementia severity. Another clue to impairment of brain energy metabolism in AD is research demonstrating reductions of key brain energy metabolite enzymes such as α-ketoglutarate dehydrogenase complex and cytochrome oxidase in this disease.129 ALCAR increases the activity of both cytochrome oxidase and α-ketoglutarate dehydrogenase in intrasynaptic but not in non-synaptic mitochondria from rat cerebral cortex.50 Rapoport et al130 and Chandrasekaran et al131 demonstrated downregulation of oxidative phosphorylation in AD, and Marcus et al132 demonstrated decreased uptake of glucose into microvessels from the temporal cortex of AD patients.

Protection against a variety of toxins

Several studies suggested increased free radical production in aging and AD. AD also is characterized by extracellular deposits of Aβ peptide and a variety of toxins, including aluminum, have been suggested to be involved in this disorder.126, 127, 128 ALCAR attenuates the effects of a variety of toxins which could contribute to its action in AD.

Possible neurotrophic effects via stimulating NGF

The cell loss in AD suggests a possible role for neurotrophic agents in the treatment of this disorder. NGF has been studied in AD and was shown to attenuate degenerative changes in cholinergic brain cells.127 ALCAR up-regulates NGF receptor expression and increases its activity, suggesting a possible neurotrophic role for ALCAR in AD.

Acetylation of proteins

ALCAR acetylates α-tubulin leading to stabilization of cytoplasmic microtubules. ALCAR also acetylates Aβ peptide (M Calvani, personal communication) and unacetylated Aβ forms potentially toxic β-sheet aggregates. Molecular simulation calculations of a fragment, Aβ(1–28), indicated that acetylation of Lys 28 could inhibit the formation of a β-sheet structure34 (Figure 3). The potential ability of ALCAR to acetylate microtubules and Aβ peptide could ameliorate the deposition of protein aggregates which comprise the two neuropathological hallmarks of AD, ie, neurofibrillary tangles and amyloid deposits. ALCAR also could acetylate -OH groups which would make them unavailable for phosphorylation by protein kinases. This could in theory reduce the hyperphosphorylation of tau protein which leads to the formation of paired helical filaments in AD.

ALCAR in geriatric depression

Mode of action of typical antidepressant drugs

One of the puzzling phenomena regarding the treatment of depression is the existence of a variety of antidepressants with no apparent similarity in molecular structure, suggesting that no apparently specific action on neurotransmitter systems or other cellular targets is needed. Indeed, there are now noradrenergic, serotoninergic, dopaminergic, cholinergic, peptidergic, and glutamatergic theories for depression, among others, demonstrating the lack of a specific dominating theory and the difficulty in finding a specific system or cellular target responsible for producing and maintaining depression. There are other serious limitations to hypotheses suggesting cathecholamine or indolamine receptor and neurotransmitter abnormalities in depression, since agonists of these systems are in general devoid of antidepressant activity. Also, evidence from animals and humans demonstrate that these neuroreceptors are affected almost immediately by drugs, but clinical improvement follows only weeks later.133 This further suggests that antidepressant action is not associated with specific short-term modulation of synaptic activity, but with extended molecular and cellular changes in neuronal activity, encompassing different levels, ie, first, second, and third messenger systems, as well as the modulation of a variety of regulatory proteins and lipids. The role of second messenger-regulated protein kinases in the brain and the action of antidepressant drugs has recently been reviewed.134

Evidence for alterations in membrane molecular dynamics in affective disorders

Over the past 25 years, evidence has accumulated in support of a possible membrane alteration in affective illness despite the existence of conflicting results. The earliest evidence included alterations in the extracellular-intracellular distribution of lithium and choline and altered Na+-K+ ATPase activity in these patients (for a review see Mallinger and Hanin135). It has been suggested that alterations in membrane molecular dynamics could contribute to the pathophysiology of some patients with bipolar affective illness.136, 137, 138, 139, 140 Other studies suggest that altered activity of membrane phospholipases (especially A2) could contribute to some of the functional membrane changes observed in some patients with affective illness (reviewed in Hibbeln et al141). Pettegrew et al142 demonstrated distinct alterations in erythrocyte membrane molecular dynamics of affective bipolar patients consisting of increased molecular motion of the phospholipid head group and hydrocarbon core areas of the membrane; those changes were modulated toward normal after 4 weeks of psychotropic treatment.

Changes in membrane composition and molecular dynamics could provide the molecular basis for alterations in membrane receptor function, cation transport and membrane enzyme activity (such as phospholipases and Na+-K+ ATPase) since a number of physical chemical studies have demonstrated the influence of membrane composition and molecular dynamics on the function of membrane proteins, such as receptors, enzymes and ion channels.143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153 Since many membrane receptors and channels contain several transmembrane helical regions,154, 155 the surrounding membrane phospholipids are poised to influence the structure and molecular dynamics of the transmembrane regions of receptors and ion channels.156, 157, 158, 159, 160, 161, 162 Membrane molecular dynamics also could influence the coupling of G-protein subunits to receptor subunits, the coupling of G-protein subunits to each other, and the coupling of G-protein subunits to membrane associated enzymes such as adenylcyclase and phospholipase C.

One central hypothesis is that some forms of affective illness are due to an alteration in membrane molecular dynamics, probably associated with altered lipid metabolism.115, 136, 138, 139, 140, 142 The alteration in membrane molecular dynamics, in turn, results in altered function of membrane proteins, such as receptors, ion channels, G-proteins, or second messenger molecular cascades. Since all of these membrane molecular constituents are highly interactive both structurally and functionally, many different molecular alterations could produce the same clinical phenotypes associated with affective disorders.

Evidence for the involvement of lipid metabolism in depression

Various data suggest alterations of fatty acids and lipid metabolism in depression. Low cholesterol levels are associated with higher prevalence of depressive symptoms and/or risk for suicide.163, 164, 165, 166, 167 Interestingly, the dexamethasone test (1 mg) in unipolar patients increased serum free fatty acids and correlated with L-tryptophan levels.168 Patients with major depression were found to have significantly decreased omega-3 fractions in cholesteryl esters and a high ratio of C20:4 omega-6/C20:5 omega-3 in phospholipid and cholesteryl esters in plasma.169 Peet et al170 and Edwards et al171 demonstrated low total plasma omega-3 polyunsaturated free fatty acids, especially docosahexanoic acid. Also, a variety of phospholipids, including phosphatidylinositols, were found to be altered in depression172 and Smythies et al173 demonstrated low phosphatidylcholine levels in erythrocyte membranes of depressed patients. Finally, Pettegrew et al120, 136, 138, 142 have suggested that one subtype of depression may involve abnormal lipid metabolism and membrane biophysical changes.

Evidence for ALCAR efficacy in depression

Tempesta et al174 conducted an open cross-over study of ALCAR and placebo in 24 depressed geriatric patients (age >70 years). These patients were treated with either 1 g of ALCAR or placebo for 1 month. ALCAR was found to be superior to placebo in patients demonstrating high baseline HDS scores.

Seven parallel, double-blind, placebo-controlled studies have examined ALCAR efficacy in various forms of geriatric depression.175, 176, 177, 178, 179, 180, 181 Six studies utilized the Hamilton rating scale among other scales to assess the depressive symptomatology, while one used the affective disorder cluster of the Sandoz Clinical Assessment Geriatric Scale.176 Five of the studies had 20–28 subjects each and two studies178, 179 had 60 subjects each (30 on ALCAR treatment and 30 on placebo).

The first of these seven studies was that of Villardita et al.175 This study examined the efficacy of ALCAR vs placebo in 28 patients of both sexes, age 65–78. The diagnostic system used was not mentioned. The baseline HDS (21 items) score was 26 ± 3, suggesting the subjects were moderately depressed. Sixteen patients were treated for 40 days with either ALCAR (1.5 g daily) or placebo. No difference was noted between these groups after 20 days. However, after 40 days of treatment ALCAR was superior to placebo (Student's t-test: P < 0.001, the effect size was above 1).

The second study was by Nasca et al.177 These authors studied 20 patients diagnosed with involutive depression by ICD-9. There were 20 subjects, age 55–75, 16 males and four females. After a washout period of 14 days, 10 received ALCAR (2 g daily) and 10 received placebo. Each of these treatments was administered in combination with mianserine for the first 20 days and then ALCAR alone for another 20 days. These patients were suffering from severe depression with baseline HDS above 40 (44 and 45) for both groups. No difference was noted between the groups after 20 days, but these authors reported a significant improvement with ALCAR treatment after 40 days (Mann-Whitney test, P < 0.001). Unfortunately, evaluation of the magnitude of change with each treatment arm was not possible since mean HDS scores were not reported for the 40-day time point.

Three double-blind studies were reported in 1990 by Garzya et al,180 Bella et al,178 and Fulgente et al.179 Garzya et al180 studied 28 patients with DSM-III-R depressive disturbances (300.4), age 70–80. Fourteen patients received ALCAR (1.5 g daily) and 14 received placebo. There was no difference in HDS (17 items) scores between the groups after 15 days of treatment, but ALCAR treatment was superior to placebo at 30 and 60 days of treatment (P < 0.01). HDS scores of patients on ALCAR improved from 22 ± 3 at baseline to 14 ± 6 at 30 days, but no further improvement was noted at 60 days (14 ± 6). HDS scores of patients on placebo improved from 20 ± 2 at baseline to 18 ± 5 at 30 days and no further improvement was noted at 60 days (18 ± 5). ALCAR treatment was better than placebo; however, the majority of patients on ALCAR demonstrated only partial remission after 60 days of treatment.

Bella et al178 and Fulgente et al179 each studied 60 patients diagnosed with DSM-III-R dysthymic disorder. Both studies had similar parallel-group, placebo-control, double-blind designs. In each study, 60 patients (30 on ALCAR and 30 on placebo) were administered ALCAR (3 g daily) or placebo, each given for 60 days. HDS scores of patients were assessed at baseline, 30, and 60 days. In the Bella et al178 study, the mean baseline HDS score for the ALCAR group was reduced from 21 to 12 at 30 days and 11 at 60 days and the mean baseline HDS score for the placebo group was reduced from 21 to 20 at 30 days and 19 at 60 days. ALCAR treatment was statistically superior to placebo treatment at 30 and 60 days. In the Fulgente et al179 study, ALCAR treatment was also superior to placebo at 30 and 60 days (P < 0.0001). The mean HDS score for the ALCAR group was reduced from 25 ± 2 at baseline to 13 ± 4 at 30 days and 12 ± 5 at 60 days. For the placebo group, HDS scores were reduced from 24 ± 3 at baseline to 22 ± 3 at 30 and 60 days. Thus, both studies encompassing 120 subjects showed a mean HDS score reduction of over 40% for the ALCAR group at 30 days compared with a mean reduction of less than 10% for placebo at the same time point, and a mean HDS reduction of 50% for ALCAR at 60 days compared with up to 10% for placebo at the identical time points. It is of note that no further substantial benefit was seen for ALCAR beyond 30 days of treatment.

Another small-scale, parallel-group, placebo-controlled, double-blind study was reported by Gecele et al.181 These authors studied 28 patients age 66–79 diagnosed with major depression according to DSM-III-R. All patients were males. Fourteen patients were treated with ALCAR (2 g a day) for 40 days and another 14 patients received placebo for an identical period of time. These authors did not specifically report mean HDS scores at baseline and 40 days. However, mean baseline HDS scores obtained by examination of a figure appearing in the manuscript indicates that the approximate mean baseline HDS score for the ALCAR-treated group was 39 and for the placebo group it was 33–34. In the ALCAR group, the mean reduction of HDS scores after 40 days appears to be 10 points, while for the placebo it appears to be less than 5 points. HDS scores of six out of 14 patients in the ALCAR group dropped under 20 while this was true for only three out of 14 in the placebo group. The ALCAR group showed a statistically significant reduction in HDS scores compared with placebo at 40 days (P < 0.05).

It is interesting to note that ALCAR also was reported to have some effect on depressive symptoms found in adult (non geriatric) patients with AIDS and AIDS-related disorders. De Simone et al176 studied 25 patients, 12 males and 13 females, mean age 36; 12 diagnosed with AIDS, six with AIDS-related complex, five with lymphadenopathy syndrome, and two with HIV-seropositive condition. All patients had depressive symptoms. The affective disorders cluster of the Sandoz Clinical Assessment Geriatric Scale was used to assess the depressive symptomatology. ALCAR treatment showed within group a statistically significant reduction in the affective disorder cluster (P < 0.001), but no difference was noted for the placebo group. Unfortunately, these authors did not provide a statistical analysis of the comparison between ALCAR and placebo groups.

Although different methodologies were used in these studies, including different sub-groups of depressed patients (ie, major depression vs dysthymic disorder), it appears that ALCAR has an antidepressant effect in a variety of depressive spectrum disorders. Such an effect is observed in geriatric depression after about 4 weeks or more of treatment. It was suggested that time to remission of patients demonstrating depression of late life is about 2 weeks longer compared with younger patients.182 On the whole, the results of the larger ALCAR studies support a role for ALCAR in depression even when compared with the results obtained with other antidepressants including fluoxetine (eg, Koran et al183).

Common membrane mechanisms in the treatment of depression

ALCAR, myo-inositol,184 omega-3 fatty acids,185 and lithium186 have been found to have antidepressant effects. Myo-inositol deficiency was reported to affect lipid metabolism.187 Recently, Pettegrew et al188 found that myo-inositol treatment increases rat brain phosphatidylethanolamine plasmalogen levels. This phospholipid strongly enhances the fusion of membranes189 and could enhance the fusion of synaptic vesicles to the synaptic plasma membrane which would enhance the release of neurotransmitters. Thus, myo-inositol affects lipid metabolism and phospholipid composition which could alter membrane physical-chemical properties. Interestingly, ALCAR increases myo-inositol levels in a model of rat diabetic neuropathy injected with streptozocin190 and delays the development of myo-inositol deficiency in the same model.191

ALCAR also can potentially supply acetyl groups needed for the synthesis of fatty acids including omega-3 fatty acids. Administration of omega-3 polyunsaturated free fatty acids could affect the ratio of saturated to unsaturated fatty acids available for synthesis of phospholipids, and thus alter the physical-chemical properties of membranes.

ALCAR shares with lithium its effect on brain phosphomonoester levels100, 192 and both tend to increase brain sphingomyelin.193 Lithium also increases CNS choline194 and inhibits the phosphatidylinositol cycle (PI).195, 196 ALCAR increases choline acetyltransferase activity and increases choline uptake into nerve terminals.197, 198 Recently, lithium was reported to inhibit PLA2 which could alter membrane phospholipid metabolism.199 In addition, lithium was reported to increase the motion of macromolecules on the membrane surface of normal human erythrocytes,140 and was reported to affect many other targets associated with the cell membrane.200, 201, 202, 203

We suggest that the antidepressant activity of ALCAR, myo-inositol, omega-3 fatty acids, and lithium are related to their effect on membrane phospholipid metabolism and membrane physical-chemical properties. Such a mechanism could affect the secretion of hormones, neurotransmitters, and cytokines, as well as affecting second messenger systems including the PI cycle and a variety of intracellular metabolites, such as prostaglandins, all suggested to be involved in the pathogenesis of depression.133 Pharmacological analysis of the broad range cellular effects of these agents in general, and those associated with lipid metabolism and membrane structure and function in particular, are needed along with pharmacological dissections at the neuroreceptor level of agents with antidepressant activity.


ALCAR contains carnitine and acetyl moieties, both of which have neurobiological properties. ALCAR is reported to affect brain energy and phospholipid metabolism and to interact with cell membranes, proteins, and enzymes. ALCAR modulates the activity of NGF, and several hormones. ALCAR demonstrates a neuromodulatory effect on synaptic morphology and on multiple neurotransmitter synaptic transmission, including that of acetylcholine. This suggests that ALCAR can affect multiple CNS systems and targets. ALCAR is reported to have beneficial effects in two major psychiatric disorders found in high prevalence in the geriatric population, that is AD and major depression. We suggest that ALCAR's mode of action in AD may involve restoration of cell membranes, as well as synaptic function, augmenting cholinergic activity, restoring brain energy, protecting against toxins, exerting neurotrophic effects via stimulating NGF, and acetylation of proteins. ALCAR's antidepressant effect may involve its effects on lipid metabolism and the cell membrane and it may share such activity with omega-3 free fatty acids, lithium, and myo-inositol. Proposed relationships between preclinical mechanisms and clinical actions of ALCAR are speculative at this time. In addition, in spite of impressive preclinical data, clinical results for ALCAR are more modest which is the case for many drugs. This review will hopefully stimulate further preclinical and clinical studies of ALCAR.


  1. 1

    Marquis NR, Fritz IB . The distribution of carnitine, acetylcarnitine, and carnitine acetyltransferase in rat tissues J Biol Chem 1965; 240: 2193–2196

    CAS  PubMed  Google Scholar 

  2. 2

    Broquist HP . Carnitine. In: Shils ME, Olson JA, Shike MS (eds) Modern Nutrition Lea & Febiger: Baltimore 1994; pp 459–465

    Google Scholar 

  3. 3

    Fritz IB . Action of carnitine on long chain fatty acid oxidation by liver Am J Physiol 1959; 197: 297–304

    CAS  PubMed  Google Scholar 

  4. 4

    Fritz IB, Yue KTN . Effects of carnitine on acetyl-CoA oxidation by heart muscle mitochondria Am J Physiol 1964; 206: 531

    CAS  PubMed  Google Scholar 

  5. 5

    Bremer J . The metabolism of fatty acid esters of carnitine by mitochondria J Biol Chem 1962; 237: 3628

    CAS  PubMed  Google Scholar 

  6. 6

    Nakano N, Fukatsu R, Fujii M, Miyazawa J, Utsumi K, Hayashi S et al. Relationship between SPECT and pathological alterations in Alzheimer's disease—a study of a case with left-hemisphere dominant lesions. (in Japanese) Seishin Shinkeigaku Zasshi – Psychiatria et Neurologia Japonica 1996; 98: 441–459

    CAS  PubMed  Google Scholar 

  7. 7

    Miyazawa S, Ozasa H, Furuta S, Osumi T, Hashimoto T, Miura S et al. Biosynthesis and turnover of carnitine acetyltransferase in rat liver J Biochem 1983; 93: 453–459

    CAS  PubMed  Google Scholar 

  8. 8

    Bieber LL . Carnitine Annu Rev Biochem 1988; 57: 261–283

    CAS  PubMed  Google Scholar 

  9. 9

    Edwards YH, Chase JF, Edwards MR, Tubbs PK . Carnitine acetyltransferase: the question of multiple forms Eur J Biochem 1974; 46: 209–215

    CAS  PubMed  Google Scholar 

  10. 10

    Marzo A, Arrigoni Martelli E, Urso R, Rocchetti M, Rizza V, Kelly JG . Metabolism and disposition of intravenously administered acetyl-L-carnitine in healthy volunteers Eur J Clin Pharmacol 1989; 37: 59–63

    CAS  PubMed  Google Scholar 

  11. 11

    Parnetti L, Gaiti A, Mecocci P, Cadini D, Senin U . Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type (published erratum appears in Eur J Clin Pharmacol 1993; 44: 604) Eur J Clin Pharmacol 1992; 42: 89–93

    CAS  PubMed  Google Scholar 

  12. 12

    Marzo A, Cardace G, Corbelleta C, Bassani E, Morabito E, Arrigoni Martelli E et al. Homeostatic equilibrium of L-carnitine family before and after i.v. administration of propionyl-L-carnitine in humans, dogs and rats Eur J Drug Metab Pharmacokinet 1991; Spec No 3: 357–363

    CAS  PubMed  Google Scholar 

  13. 13

    Kuratsune H, Watanabe Y, Yamaguti K, Jacobsson G, Takahashi M, Machii T et al. High uptake of [2-11C]acetyl-L-carnitine into the brain: a PET study Biochem Biophys Res Commun 1997; 231: 488–493

    CAS  PubMed  Google Scholar 

  14. 14

    Aureli T, Di Cocco M, Puccetti C, Ricciolini R, Scalibastri M, Miccheli A et al. Acetyl-L- carnitine modulates glucose metabolism and stimulates glycogen synthesis in rat brain Brain Res 1998; 796: 75–81

    CAS  PubMed  Google Scholar 

  15. 15

    Capecchi PL, Laghi Pasini F, Quartarolo E, Di Perri T . Carnitines increase plasma levels of adenosine and ATP in humans Vasc Med 1997; 2: 77–81

    CAS  PubMed  Google Scholar 

  16. 16

    Rao KV, Mawal YR, Qureshi IA . Progressive decrease of cerebral cytochrome C oxidase activity in sparse-fur mice: role of acetyl-L-carnitine in restoring the ammonia-induced cerebral energy depletion Neurosci Lett 1997; 224: 83–86

    CAS  PubMed  Google Scholar 

  17. 17

    Rosenthal RE, Williams R, Bogaert YE, Getson PR, Fiskum G . Prevention of postischemic canine neurological injury through potentiation of brain energy metabolism by acetyl-L-carnitine Stroke 1992; 23: 1312–1318

    CAS  PubMed  Google Scholar 

  18. 18

    Jeulin C, Soufir JC, Marson J, Paquignon M, Dacheux JL . Acetylcarnitine and spermatozoa: relationship with epididymal maturation and motility in the boar and man. (In French) Reprod Nutr Dev 1988; 28: 1317–1327

    CAS  PubMed  Google Scholar 

  19. 19

    Fredholm BB . Purinoceptors in the nervous system Pharmacol Toxicol 1995; 76: 228–239

    CAS  PubMed  Google Scholar 

  20. 20

    Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB . Neuroprotective role of adenosine in cerebral ischaemia Trends Pharmacol Sci 1992; 13: 439–445

    CAS  PubMed  Google Scholar 

  21. 21

    Kobayashi S, Zimmermann H, Millhorn DE . Chronic hypoxia enhances adenosine release in rat PC12 cells by altering adenosine metabolism and membrane transport J Neurochem 2000; 74: 621–632

    CAS  PubMed  Google Scholar 

  22. 22

    Kobayashi S, Conforti L, Pun RY, Millhorn DE . Adenosine modulates hypoxia-induced responses in rat PC12 cells via the A2A receptor J Physiol 1998; 508: 95–107

    CAS  PubMed  PubMed Central  Google Scholar 

  23. 23

    Hoppel C . The physiological role of carnitine. In: Ferrari R, Di Mauro S, Sherwood G (eds) L-Carnitine and Its Role in Medicine: From Function to Therapy Academic Press: New York 1999; pp 5–20

    Google Scholar 

  24. 24

    Parvin R, Pande SV . Enhancement of mitochondrial carnitine and carnitine acylcarnitine translocase-mediated transport of fatty acids into liver mitochondria under ketogenic conditions J Biol Chem 1979; 254: 5423–5429

    CAS  PubMed  Google Scholar 

  25. 25

    Villa RF, Turpeenoja L, Benzi G, Giuffrida SM . Action of L-acetylcarnitine on age-dependent modifications of mitochondrial membrane proteins from rat cerebellum Neurochem Res 1988; 13: 909–916

    CAS  PubMed  Google Scholar 

  26. 26

    Aureli T, Miccheli A, Ricciolini R, Di Cocco ME, Ramacci MT, Angelucci L et al. Aging brain: effect of acetyl-L-carnitine treatment on rat brain energy and phospholipid metabolism. A study by 31P and 1H NMR spectroscopy Brain Res 1990; 526: 108–112

    CAS  PubMed  Google Scholar 

  27. 27

    Arienti G, Ramacci MT, Maccari F, Casu A, Corazzi L . Acetyl-L-carnitine influences the fluidity of brain microsomes and of liposomes made of rat brain microsomal lipid extracts Neurochem Res 1992; 17: 671–675

    CAS  PubMed  Google Scholar 

  28. 28

    Butterfield DA, Rangachari A . Acetylcarnitine increases membrane cytoskeletal protein–protein interactions Life Sci 1993; 52: 297–303

    CAS  PubMed  Google Scholar 

  29. 29

    Arduini A, Rossi M, Mancinelli G, Belfiglio M, Scurti R, Radatti G et al. Effect of L-carnitine and acetyl-L-carnitine on the human erythrocyte membrane stability and deformability Life Sci 1990; 47: 2395–2400

    CAS  PubMed  Google Scholar 

  30. 30

    Paradies G, Ruggiero FM, Gadaleta MN, Quagliariello E . The effect of aging and acetyl-L-carnitine on the activity of the phosphate carrier and on the phospholipid composition in rat heart mitochondria Biochim Biophys Acta 1992; 1103: 324–326

    CAS  PubMed  Google Scholar 

  31. 31

    Pieklik JR, Guynn RW . Equilibrium constants of the reactions of choline acetyltransferase, carnitine acetyltransferase, and acetylcholinesterase under physiological conditions J Biol Chem 1975; 250: 4445–4450

    CAS  PubMed  Google Scholar 

  32. 32

    Guynn RW, Veech RL . The equilibrium constants of the adenosine triphosphate hydrolysis and the adenosine triphosphate-citrate lyase reactions J Biol Chem 1973; 248: 6966–6972

    CAS  PubMed  Google Scholar 

  33. 33

    Colucci WJ, Gandour RD . Carnitine acetyltransferase: A review of its biology, enzymology, and bioorganic chemistry Bioorg Chem 1988; 16: 307–334

    CAS  Google Scholar 

  34. 34

    McClure RJ, Panchalingam K, Stanley JA, Pettegrew JW . Comparison of the conformation of amyloid beta (1–28) peptide fragment with its Lys28 N-acetyl derivative Soc Neurosci Abstr 1997; 23: 1883–1883

    Google Scholar 

  35. 35

    Pisano C, Camerini B, Castorina M, Olivi A, Ambrosini A, Calvani M . Acetyl-L-carnitine is involved in protein acetylation Development, Cell Differentiation and Cancer 1996, 9th International Conference ISD, Pisa, Italy

  36. 36

    Swamy-Mruthinti S, Carter AL . Acetyl-L-carnitine decreases glycation of lens proteins: in vitro studies Exp Eye Res 1999; 69: 109–115

    CAS  PubMed  Google Scholar 

  37. 37

    Nadler SG, Strobel HW . Role of electrostatic interactions in the reaction of NADPH-cytochrome P-450 reductase with cytochromes P-450 Arch Biochem Biophys 1988; 261: 418–429

    CAS  PubMed  Google Scholar 

  38. 38

    Shen S, Strobel HW . Role of lysine and arginine residues of cytochrome P450 in the interaction between cytochrome P4502B1 and NADPH-cytochrome P450 reductase Arch Biochem Biophys 1993; 304: 257–265

    CAS  PubMed  Google Scholar 

  39. 39

    Mathews FS, Argos P, Levine M . The structure of b5 at 2.0 Angstrom resolution Cold Spring Harb Symp Quant Biol 1972; 36: 387–395

    CAS  PubMed  Google Scholar 

  40. 40

    Angelucci L, Ramacci MT, Taglialatela G, Hulsebosch C, Morgan B, Werrbach-Perez K et al. Nerve growth factor binding in aged rat central nervous system: effect of acetyl-L-carnitine J Neurosci Res 1988; 20: 491–496

    CAS  PubMed  Google Scholar 

  41. 41

    De Simone R, Ramacci MT, Aloe L . Effect of acetyl-L-carnitine on forebrain cholinergic neurons of developing rats Int J Dev Neurosci 1991; 9: 39–46

    CAS  PubMed  Google Scholar 

  42. 42

    Taglialatela G, Angelucci L, Ramacci MT, Werrbach-Perez K, Jackson GR, Perez-Polo JR . Acetyl-L-carnitine enhances the response of PC12 cells to nerve growth factor Brain Res Dev Brain Res 1991; 59: 221–230

    CAS  PubMed  Google Scholar 

  43. 43

    Taglialatela G, Angelucci L, Ramacci MT, Werrbach-Perez K, Jackson GR, Perez-Polo JR . Stimulation of nerve growth factor receptors in PC12 by acetyl-L-carnitine Biochem Pharmacol 1992; 44: 577–585

    CAS  PubMed  Google Scholar 

  44. 44

    Taglialatela G, Navarra D, Olivi A, Ramacci MT, Werrbach-Perez K, Perez-Polo JR et al. Neurite outgrowth in PC12 cells stimulated by acetyl-L-carnitine arginine amide Neurochem Res 1995; 20: 1–9

    CAS  PubMed  Google Scholar 

  45. 45

    Taglialatela G, Navarra D, Cruciani R, Ramacci MT, Alema GS, Angelucci L . Acetyl-L-carnitine treatment increases nerve growth factor levels and choline acetyltransferase activity in the central nervous system of aged rats Exp Gerontol 1994; 29: 55–66

    CAS  PubMed  Google Scholar 

  46. 46

    Piovesan P, Pacifici L, Taglialatela G, Ramacci MT, Angelucci L . Acetyl-L-carnitine treatment increases choline acetyltransferase activity and NGF levels in the CNS of adult rats following total fimbria-fornix transection Brain Res 1994; 633: 77–82

    CAS  PubMed  Google Scholar 

  47. 47

    Taglialatela G, Caprioli A, Giuliani A, Ghirardi O . Spatial memory and NGF levels in aged rats: natural variability and effects of acetyl-L-carnitine treatment Exp Gerontol 1996; 31: 577–587

    CAS  PubMed  Google Scholar 

  48. 48

    McDonald NQ, Lapatto R, Murray-Rust J, Gunning J, Wlodawer A, Blundell TL . New protein fold revealed by a 2.3-A resolution structure of nerve growth factor Nature 1991; 354: 411–414

    CAS  PubMed  Google Scholar 

  49. 49

    Liu Y, Rosenthal RE, Stark-Reed P, Fiskum G . Inhibition of postcardiac arrest brain protein oxidation by acetyl-L-carnitine Free Radic Biol Med 1993; 15: 667–670

    CAS  PubMed  Google Scholar 

  50. 50

    Gorini A, D'Angelo A, Villa RF . Action of L-acetylcarnitine on different cerebral mitochondrial populations from cerebral cortex Neurochem Res 1998; 23: 1485–1491

    CAS  PubMed  Google Scholar 

  51. 51

    Gorini A, Ghigini B, Villa RF . Acetylcholinesterase activity of synaptic plasma membranes during ageing: effect of L-acetylcarnitine Dementia 1996; 7: 147–154

    CAS  PubMed  Google Scholar 

  52. 52

    Terwel D, Prickaerts J, Meng F, Jolles J . Brain enzyme activities after intracerebroventricular injection of streptozotocin in rats receiving acetyl-L-carnitine Eur J Pharmacol 1995; 287: 65–71

    CAS  PubMed  Google Scholar 

  53. 53

    Pascale A, Milano S, Corsico N, Lucchi L, Battaini F, Martelli EA et al. Protein kinase C activation and anti-amnesic effect of acetyl-L-carnitine: in vitro and in vivo studies Eur J Pharmacol 1994; 265: 1–7

    CAS  PubMed  Google Scholar 

  54. 54

    Florio T, Meucci O, Grimaldi M, Ventra C, Cocozza E, Avallone A et al. Effect of acetyl-L-carnitine treatment on brain adenylate cyclase activity in young and aged rats Eur Neuropsychopharmacol 1993; 3: 95–101

    CAS  PubMed  Google Scholar 

  55. 55

    Villa RF, Gorini A . Action of L-acetylcarnitine on different cerebral mitochondrial populations from hippocampus and striatum during aging Neurochem Res 1991; 16: 1125–1132

    CAS  PubMed  Google Scholar 

  56. 56

    Karpusas M, Holland D, Remington SJ . 1.9-Å structures of ternary complexes of citrate synthase with D- and L-malate: mechanistic implications Biochemistry 1991; 30: 6024–6031

    CAS  PubMed  Google Scholar 

  57. 57

    Lappalainen P, Watmough NJ, Greenwood C, Saraste M . Electron transfer between cytochrome c and the isolated CuA domain: identification of substrate-binding residues in cytochrome c oxidase Biochemistry 1995; 34: 5824–5830

    CAS  PubMed  Google Scholar 

  58. 58

    Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein Science 1991; 253: 872–879

    CAS  PubMed  Google Scholar 

  59. 59

    Slemmon JR . Sequence analysis of a proteolyzed site in Drosophila choline acetyltransferase J Neurochem 1989; 52: 1898–1904

    CAS  PubMed  Google Scholar 

  60. 60

    Sutton RB, Sprang SR . Structure of the protein kinase Cbeta phospholipid-binding C2 domain complexed with Ca2+ Structure 1998; 6: 1395–1405

    CAS  PubMed  Google Scholar 

  61. 61

    Tesmer JJ, Sunahara RK, Gilman AG, Sprang SR . Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha. GTPgammaS Science 1997; 278: 1907–1916

    CAS  PubMed  Google Scholar 

  62. 62

    Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai L-H . Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration Nature 1999; 402: 615–622

    CAS  PubMed  Google Scholar 

  63. 63

    Onofrj M, Bodis-Wollner I, Pola P, Calvani M . Central cholinergic effects of levo-acetylcarnitine Drugs Exp Clin Res 1983; 9: 161–169

    CAS  Google Scholar 

  64. 64

    Angelucci L, Ramacci MT . Hypothalamo-pituitary-adenocortical function in aging: effects of acetyl–L–carnitine. In: De Simone R, Martelli EA (eds) Stress, Immunity and Ageing—A Role for Acetyl–L–carnitine Excerpta Medica: Amsterdam 1989; pp 109–118

    Google Scholar 

  65. 65

    Costa A, Martignoni E, Bono G, Monzani A, Nappi G . Acetyl–L–carnitine, adrenocortical hyperactivity and pathological aging brain. In: De Simone C, Martelli EA (eds) Stress, Immunity and Ageing—A Role for Acetyl-–L–carnitine Excerpta Medica: Amsterdam 1989; pp 119–124

    Google Scholar 

  66. 66

    Ghirardi O, Caprioli A, Ramacci MT, Angelucci L . Effect of long-term acetyl-L-carnitine on stress-induced analgesia in the aging rat Exp Gerontol 1994; 29: 569–574

    CAS  PubMed  Google Scholar 

  67. 67

    De Simone C, Calvani M, Catania S, Trinchieri V, Di Fabio S, Santini G et al. Acetyl–L–carnitine as a modulator of the neuro-endocrine-immune interaction in HIV + subjects. In: De Simone C, Martelli EA (eds) Stress, Immunity and Ageing—A Role for Acetyl–L–carnitine Excerpta Medica: Amsterdam 1989; pp 125–138

    Google Scholar 

  68. 68

    Fraschini F, Esposti D, Demartini G, Scaglione F, Lucini V, Mariani et al. In vivo and in vitro studies on modulation of the pineal endocrine function by L-acetyl-carnitine in the rat Psychoneuroendocrinology 1991; 16: 417–422

    CAS  PubMed  Google Scholar 

  69. 69

    Esposti D, Mariani M, Demartini G, Lucini V, Fraschini F, Mancia M . Modulation of melatonin secretion by acetyl-L-carnitine in adult and old rats J Pineal Res 1994; 17: 132–136

    CAS  PubMed  Google Scholar 

  70. 70

    Krsmanovic LZ, Virmani MA, Stojilkovic SS, Catt KJ . Stimulation of gonadotropin-releasing hormone secretion by acetyl-L-carnitine in hypothalamic neurons and GT1 neuronal cells Neurosci Lett 1994; 165: 33–36

    CAS  PubMed  Google Scholar 

  71. 71

    Bidzinska B, Petraglia F, Angioni S, Genazzani AD, Criscuolo M, Ficarra G et al. Effect of different chronic intermittent stressors and acetyl-L-carnitine on hypothalamic beta-endorphin and GnRH and on plasma testosterone levels in male rats Neuroendocrinology 1993; 57: 985–990

    CAS  PubMed  Google Scholar 

  72. 72

    Krsmanovic LZ, Virmani MA, Stojilkovic SS, Catt KJ . Actions of acetyl-L-carnitine on the hypothalamo-pituitary-gonadal system in female rats J Steroid Biochem Mol Biol 1992; 43: 351–358

    CAS  PubMed  Google Scholar 

  73. 73

    Kentroti S, Ramacci MT, Vernadakis A . Acetyl-L-carnitine has a neuromodulatory influence on neuronal phenotypes during early embryogenesis in the chick embryo Brain Res Dev Brain Res 1992; 70: 259–266

    CAS  PubMed  Google Scholar 

  74. 74

    Pomponi MG, Neri G . Butyrate and acetyl-carnitine inhibit the cytogenetic expression of the fragile X in vitro Am J Med Genet 1994; 51: 447–450

    CAS  PubMed  Google Scholar 

  75. 75

    Laschi R, Badiali DG, Bonvicini F, Centurione L . Ultrastructural aspects of aging rat hippocampus after long-term administration of acetyl-L-carnitine Int J Clin Pharmacol Res 1990; 10: 59–63

    CAS  PubMed  Google Scholar 

  76. 76

    Bertoni-Freddari C, Fattoretti P, Casoli T, Spagna C, Casell U . Dynamic morphology of the synaptic junctional areas during aging: the effect of chronic acetyl-L-carnitine administration Brain Res 1994; 656: 359–366

    CAS  PubMed  Google Scholar 

  77. 77

    Bertoni-Freddari C, Fattoretti P, Caselli U, Paoloni R . Acetylcarnitine modulation of the morphology of rat hippocampal synapses Anal Quant Cytol Histol 1996; 18: 275–278

    CAS  PubMed  Google Scholar 

  78. 78

    Curti D, Dagani F, Galmozzi MR, Marzatico F . Effect of aging and acetyl-L-carnitine on energetic and cholinergic metabolism in rat brain regions Mech Ageing Dev 1989; 47: 39–45

    CAS  PubMed  Google Scholar 

  79. 79

    Davis S, Markowska AL, Wenk GL, Barnes CA . Acetyl-L-carnitine: behavioral, electrophysiological, and neurochemical effects Neurobiol Aging 1993; 14: 107–115

    CAS  PubMed  Google Scholar 

  80. 80

    De Falco FA, D'Angelo E, Grimaldi G, Scafuro F, Sachez F, Caruso G . Effect of the chronic treatment with L-acetylcarnitine in Down's syndrome. (In Italian) Clinica Terapeutica 1994; 144: 123–127

    CAS  PubMed  Google Scholar 

  81. 81

    Ratnakumari L, Qureshi IA, Maysinger D, Butterworth RF . Developmental deficiency of the cholinergic system in congenitally hyperammonemic spf mice: effect of acetyl-L-carnitine J Pharmacol Exp Ther 1995; 274: 437–443

    CAS  PubMed  Google Scholar 

  82. 82

    Piovesan P, Quatrini G, Pacifici L, Taglialatela G, Angelucci L . Acetyl-L-carnitine restores choline acetyltransferase activity in the hippocampus of rats with partial unilateral fimbria-fornix transection Int J Dev Neurosci 1995; 13: 13–19

    CAS  PubMed  Google Scholar 

  83. 83

    Prickaerts J, Blokland A, Honig W, Meng F, Jolles J . Spatial discrimination learning and choline acetyltransferase activity in streptozotocin-treated rats: effects of chronic treatment with acetyl-L-carnitine Brain Res 1995; 674: 142–146

    CAS  PubMed  Google Scholar 

  84. 84

    Castorina M, Ferraris L . Acetyl-L-carnitine affects aged brain receptorial system in rodents Life Sci 1994; 54: 1205–1214

    CAS  PubMed  Google Scholar 

  85. 85

    Castorina M, Ambrosini AM, Giuliani A, Pacifici L, Ramacci MT, Angelucci L . A cluster analysis study of acetyl-L-carnitine effect on NMDA receptors in aging Exp Gerontol 1993; 28: 537–548

    CAS  PubMed  Google Scholar 

  86. 86

    Harsing LGJ, Sershen H, Toth E, Hashim A, Ramacci MT, Lajtha A . Acetyl-L-carnitine release, dopamine in rat corpus striatum: an in vivo microdialysis study Eur J Pharmacol 1992; 218: 117–121

    CAS  PubMed  Google Scholar 

  87. 87

    Imperato A, Ramacci MT, Angelucci L . Acetyl-L-carnitine enhances acetylcholine release in the striatum and hippocampus of awake freely moving rats Neurosci Lett 1989; 107: 251–255

    CAS  PubMed  Google Scholar 

  88. 88

    Sershen H, Harsing LJ, Banay-Schwartz M, Hashim A, Ramacci MT, Lajtha A . Effect of acetyl-L-carnitine on the dopaminergic system in aging brain J Neurosci Res 1991; 30: 555–559

    CAS  PubMed  Google Scholar 

  89. 89

    Janiri L, Falcone M, Persico A, Tempesta E . Activity of L-carnitine and L-acetylcarnitine on cholinoceptive neocortical neurons of the rat in vivo J Neural Transm 1991; 86: 135–146

    CAS  Google Scholar 

  90. 90

    Fariello RG, Ferraro TN, Golden GT, DeMattei M . Systemic acetyl-L-carnitine elevates nigral levels of glutathione and GABA Life Sci 1988; 43: 289–292

    CAS  PubMed  Google Scholar 

  91. 91

    Tempesta E, Janiri L, Pirrongelli C . Stereospecific effects of acetylcarnitine on the spontaneous activity of brain-stem neurons and their responses to acetylcholine and serotonin Neuropharmacology 1985; 24: 43–50

    CAS  PubMed  Google Scholar 

  92. 92

    Toth E, Harsing LGJ, Sershen H, Ramacci MT, Lajtha A . Effect of acetyl-L-carnitine on extracellular amino acid levels in vivo in rat brain regions Neurochem Res 1993; 18: 573–578

    CAS  PubMed  Google Scholar 

  93. 93

    Santarelli M, Granato A, Sbriccoli A, Gobbi G, Janiri L, Minciacchi D . Alterations of the thalamo-cortical system in rats prenatally exposed to ethanol are prevented by concurrent administration of acetyl-L-carnitine Brain Res 1995; 698: 241–247

    CAS  PubMed  Google Scholar 

  94. 94

    Steffen V, Santiago M, de la Cruz CP, Revilla E, Machado A, Cano J . Effect of intraventricular injection of 1-methyl-4-phenylpyridinium: protection by acetyl-L-carnitine Hum Exp Toxicol 1995; 14: 865–871

    CAS  PubMed  Google Scholar 

  95. 95

    Forloni G, Angeretti N, Smiroldo S . Neuroprotective activity of acetyl-L-carnitine: studies in vitro J Neurosci Res 1994; 37: 92–96

    CAS  PubMed  Google Scholar 

  96. 96

    Galli G, Fratelli M . Activation of apoptosis by serum deprivation in a teratocarcinoma cell line: inhibition by L-acetylcarnitine Exp Cell Res 1993; 204: 54–60

    CAS  PubMed  Google Scholar 

  97. 97

    Dell'Anna E, Iuvone L, Calzolari S, Geloso MC . Effect of acetyl-L-carnitine on hyperactivity and spatial memory deficits of rats exposed to neonatal anoxia Neurosci Lett 1997; 223: 201–205

    CAS  PubMed  Google Scholar 

  98. 98

    Caprioli A, Markowska AL, Olton DS . Acetyl–L–carnitine: chronic treatment improves spatial acquisition in a new environment in aged rats J Gerontol A Biol Sci Med Sci 1995; 50: B232–B236

    CAS  PubMed  Google Scholar 

  99. 99

    Spagnoli A, Lucca U, Menasce G, Bandera L, Cizza G, Forloni G et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease Neurology 1991; 41: 1726–1732

    CAS  PubMed  Google Scholar 

  100. 100

    Pettegrew JW, Klunk WE, Panchalingam K, Kanfer JN, McClure RJ . Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease Neurobiol Aging 1995; 16: 1–4

    CAS  PubMed  Google Scholar 

  101. 101

    Thal LJ, Carta A, Clarke WR, Ferris SH, Friedland RP, Petersen RC et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease Neurology 1996; 47: 705–711

    CAS  PubMed  Google Scholar 

  102. 102

    Brooks JO, Yesavage JA, Carta A, Bravi D . Acetyl-L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach Int Psychogeriatr 1998; 10: 193–203

    PubMed  Google Scholar 

  103. 103

    Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI . A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group JAMA 1994; 271: 985–991

    CAS  PubMed  Google Scholar 

  104. 104

    Maltby N, Broe GA, Creasey H, Jorm AF, Christensen H, Brooks WS . Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial BMJ 1994; 308: 879–883

    CAS  PubMed  PubMed Central  Google Scholar 

  105. 105

    Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M . Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists’ Collaboration JAMA 1998; 280: 1777–1782

    CAS  PubMed  Google Scholar 

  106. 106

    Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial BMJ 1999; 318: 633–638

    CAS  PubMed  PubMed Central  Google Scholar 

  107. 107

    Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT . A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group Neurology 1998; 50: 136–145

    CAS  PubMed  PubMed Central  Google Scholar 

  108. 108

    van Gool WA . Efficacy of donepezil in Alzheimer′s disease: fact or artifact? Neurology 1999; 52: 218–219

    CAS  PubMed  Google Scholar 

  109. 109

    Bayer T . Commentary: another piece of the Alzheimer's jigsaw BMJ 1999; 318: 639

    CAS  PubMed  Google Scholar 

  110. 110

    Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL . Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease Neurology 1998; 50: 669–677

    CAS  PubMed  Google Scholar 

  111. 111

    Ellison DW, Beal MF, Martin JB . Phosphoethanolamine and ethanolamine are decreased in Alzheimer's disease and Huntington's disease Brain Res 1987; 417: 389–392

    CAS  PubMed  Google Scholar 

  112. 112

    Miatto O, Gonzalez G, Buonanno F, Growdon JH . In vitro31P NMR spectroscopy detects altered phospholipid metabolism in Alzheimer's disease Can J Neurol Sci 1986; 13: 535–539

    CAS  PubMed  Google Scholar 

  113. 113

    Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ . Evidence for a membrane defect in Alzheimer disease brain Proc Natl Acad Sci USA 1992; 89: 1671–1675

    CAS  PubMed  Google Scholar 

  114. 114

    Pettegrew JW, Kopp SJ, Minshew NJ, Glonek T, Feliksik JM, Tow JP et al. 31P nuclear magnetic resonance studies of phosphoglyceride metabolism in developing and degenerating brain: preliminary observations J Neuropathol Exp Neurol 1987; 46: 419–430

    CAS  PubMed  Google Scholar 

  115. 115

    Pettegrew JW, Minshew NJ, Cohen MM, Kopp SJ, Glonek T . P-31 NMR changes in Alzheimer's and Huntington's disease brain Neurology 1984; 34: (Suppl 1) 281–281

    Google Scholar 

  116. 116

    Pettegrew JW, Moossy J, Withers G, McKeag D, Panchalingam K . 31P nuclear magnetic resonance study of the brain in Alzheimer's disease J Neuropathol Exp Neurol 1988; 47: 235–248

    CAS  PubMed  Google Scholar 

  117. 117

    Pettegrew JW, Panchalingam K, Klunk WE, McClure RJ, Muenz LR . Alterations of cerebral metabolism in probable Alzheimer's disease; a preliminary study Neurobiol Aging 1994; 15: 117–132

    CAS  PubMed  Google Scholar 

  118. 118

    Smith CD, Gallenstein LG, Layton WJ, Kryscio RJ, Markesbery WR . 31P magnetic resonance spectroscopy in Alzheimer's and Pick's disease Neurobiol Aging 1993; 14: 85–92

    CAS  PubMed  Google Scholar 

  119. 119

    Cuenod C-A, Kaplan DB, Michot J-L, Jehenson P, Leroy-Willig A, Forette F et al. Phospholipid abnormalities in early Alzheimer's disease Arch Neurol 1995; 52: 89–94

    CAS  PubMed  Google Scholar 

  120. 120

    Pettegrew JW, Klunk WE, Kanal E, Panchalingam K, McClure RJ . Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia Neurobiol Aging 1995; 16: 973–975

    CAS  PubMed  Google Scholar 

  121. 121

    Lassmann H, Fischer P, Jellinger K . Synaptic pathology of Alzheimer's disease Ann N Y Acad Sci 1993; 695: 59–64

    CAS  PubMed  Google Scholar 

  122. 122

    Liu X, Erikson C, Brun A . Cortical synaptic changes and gliosis in normal aging, Alzheimer's disease and frontal lobe degeneration Dementia 1996; 7: 128–134

    CAS  PubMed  Google Scholar 

  123. 123

    Wakabayashi K, Honer WG, Masliah E . Synapse alterations in the hippocampal-entorhinal formation in Alzheimer's disease with and without Lewy body disease Brain Res 1994; 667: 24–32

    CAS  PubMed  Google Scholar 

  124. 124

    Yao PJ, Coleman PD . Reduced O-glycosylated clathrin assembly protein AP180: implication for synaptic vesicle recycling dysfunction in Alzheimer's disease Neurosci Lett 1998; 252: 33–36

    CAS  PubMed  Google Scholar 

  125. 125

    Davidsson P, Blennow K . Neurochemical dissection of synaptic pathology in Alzheimer's disease Int Psychogeriatr 1998; 10: 11–23

    CAS  PubMed  Google Scholar 

  126. 126

    Sunderland T, Molchan SE, Zubenko GS . Biological markers in Alzheimer disease. In: Bloom M, Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress Raven Press: New York 1995; pp 1389–1399

    Google Scholar 

  127. 127

    Marin DB, Davis K . Experimental therapeutics. In: Bloom PE, Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress Raven Press: New York 1995; pp 1417–1426

    Google Scholar 

  128. 128

    Rapoport SI . Anatomic and functional brain imaging in Alzheimer's disease. In: Bloom PE, Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress Raven Press: New York 1995; pp 1401–1415

    Google Scholar 

  129. 129

    Kish SJ . Brain energy metabolizing enzymes in Alzheimer's disease: alpha-ketoglutarate dehydrogenase complex and cytochrome oxidase Ann N Y Acad Sci 1997; 826: 218–228

    CAS  PubMed  Google Scholar 

  130. 130

    Rapoport SI, Hatanpaa K, Brady DR, Chandrasekaran K . Brain energy metabolism, cognitive function and down-regulated oxidative phosphorylation in Alzheimer disease Neurodegeneration 1996; 5: 473–476

    CAS  PubMed  Google Scholar 

  131. 131

    Chandrasekaran K, Hatanpaa K, Brady DR, Rapoport SI . Evidence for physiological down-regulation of brain oxidative phosphorylation in Alzheimer's disease Exp Neurol 1996; 142: 80–88

    CAS  PubMed  Google Scholar 

  132. 132

    Marcus DL, de Leon MJ, Goldman J, Logan J, Christman DR, Wolf AP et al. Altered glucose metabolism in microvessels from patients with Alzheimer's disease Ann Neurol 1989; 26: 91–94

    CAS  PubMed  Google Scholar 

  133. 133

    Leonard BE . Action mechanism of antidepressants. In: Honig A, Van Praag HM (eds) Depression: Neurobiological, Psychological and Therapeutic Advances John Wiley & Sons: New York 1997; pp 459–470

    Google Scholar 

  134. 134

    Popoli M, Brunello N, Perez J, Racagni G . Second messenger-regulated protein kinases in the brain: their functional role and the action of antidepressant drugs J Neurochem 2000; 74: 21–33

    CAS  PubMed  Google Scholar 

  135. 135

    Mallinger AG, Hanin I . Membrane transport processes in affective illness. In: Usdin E, Hanin I (eds) Biological Markers in Psychiatry and Neurology Pergamon Press: New York 1982; pp 137–151

    Google Scholar 

  136. 136

    Pettegrew JW, Nichols JS, Minshew NJ, Rush AJ, Stewart RM . Membrane biophysical studies of lymphocytes and erythrocytes in manic-depressive illness J Affect Disord 1982; 4: 237–247

    CAS  PubMed  Google Scholar 

  137. 137

    Pettegrew JW, Woessner DE, Minshew NJ . Sodium-23 NMR analysis of human whole blood, erythrocyte and plasma. Chemical shift, spin relaxation and intracellular sodium concentration studies J Magn Reson 1984; 57: 185–196

    CAS  Google Scholar 

  138. 138

    Pettegrew JW . Toward a molecular basis for affective disorders. In: Rush A, Altshuler K (eds) Depression—Basic Mechanisms, Diagnosis and Treatment Guilford Press: New York 1986; pp 183–204

    Google Scholar 

  139. 139

    Pettegrew JW, Post JFM, Panchalingam K . 7Li study of normal human erythrocytes J Magn Reson 1987; 71: 504–519

    CAS  Google Scholar 

  140. 140

    Pettegrew JW, Short JW, Woessner RD, Strychor S, McKeag DW, Armstrong J et al. The effect of lithium on the membrane molecular dynamics of normal human erythrocytes Biol Psychiatry 1987; 22: 857–871

    CAS  PubMed  Google Scholar 

  141. 141

    Hibbeln JR, Palmer JW, Davis JM . Are disturbances in lipid-protein interactions by Phospholipase-A2 a predisposing factor in affective illness Biol Psychiatry 1989; 25: 945–961

    CAS  PubMed  Google Scholar 

  142. 142

    Pettegrew JW, Minshew NJ, Spiker D, Tretta M, Strychor S, McKeag D et al. Alterations in membrane molecular dynamics in erythrocytes of patients with affective illness Depression 1993; 1: 88–100

    Google Scholar 

  143. 143

    Cullis PR, DeKruijff B . Lipid polymorphism and the functional roles of lipids in biological membranes Biochim Biophys Acta 1979; 559: 399–420

    CAS  PubMed  Google Scholar 

  144. 144

    Cohen CM . The molecular organization of the red cell membrane skeleton Semin Hematol 1983; 20: 141–158

    CAS  PubMed  Google Scholar 

  145. 145

    Benga G, Holmes RP . Interactions between components in biological membranes and their implications for membrane function Prog Biophys Mol Biol 1984; 43: 195–257

    CAS  PubMed  Google Scholar 

  146. 146

    Carruthers A, Melchior D . A rapid method of reconstituting human erythrocyte sugar transport proteins Biochemistry 1984; 23: 2712–2718

    CAS  PubMed  Google Scholar 

  147. 147

    Connolly T, Carruthers A, Melchior D . Effects of biolayer cholesterol of human erythrocyte hexose transport protein activity in synthetic lecithin bilayers Biochemistry 1985; 24: 2865–2873

    CAS  PubMed  Google Scholar 

  148. 148

    Farmer BT, Harmon TM, Butterfield DA . ESR study of the erythrocyte membrane skeletal protein network: influence of the state of aggregation of spectrin on the physical state of membrane proteins, bilayer lipids, and cell surface carbohydrates Biochim Biophys Acta 1985; 821: 420–430

    CAS  PubMed  Google Scholar 

  149. 149

    Storch J, Kleinfeld A . The lipid structure of biological membranes Trends Biochem Sci 1985; 10: 418–421

    CAS  Google Scholar 

  150. 150

    Carruthers A, Melchior D . How bilayer lipids affect membrane protein activity Trends Biochem Sci 1986; 11: 331–335

    CAS  Google Scholar 

  151. 151

    DeLisle RC, Williams JA . Regulation of membrane fusion in secretory exocytosis Annu Rev Physiol 1986; 48: 225–238

    CAS  Google Scholar 

  152. 152

    Fong TM, McNamee MG . Correlation between acetylcholine receptor function and structural properties of membranes Biochemistry 1986; 25: 830–840

    CAS  PubMed  Google Scholar 

  153. 153

    DeKruijff B . Polymorphic regulation of membrane lipid composition Nature 1987; 329: 587–588

    CAS  Google Scholar 

  154. 154

    Hanley M, Jackson T . Return of the magnificient seven Nature 1987; 329: 766–767

    CAS  PubMed  Google Scholar 

  155. 155

    Hall Z . Three of a kind: the b-adrenergic receptor, the muscarinic acetylcholine receptor, the rhodopsin Trends Neurosci 1987; 10: 99–101

    CAS  Google Scholar 

  156. 156

    Prives H, Fulton A, Penman S, Daniels MP, Christian CN . Interaction of the cytoskeleton framework with acetylcholine receptors on the surface of embryonic muscle cells in culture J Cell Biol 1982; 92: 231–236

    CAS  PubMed  Google Scholar 

  157. 157

    Peng H, Froehner S . Association of the postsynaptic 43K protein with newly formed acetylcholine receptor clusters in cultured muscle cells J Cell Biol 1985; 100: 1698–1705

    CAS  PubMed  Google Scholar 

  158. 158

    Froehner S . The role of the postsynaptic cytoskeleton in AChR organization Trends Neurosci 1986; 9: 37–41

    CAS  Google Scholar 

  159. 159

    Hirokawa N . Quick-freeze, deep-etch visualization of the axonal cytoskeleton Trends Neurosci 1986; 9: 67–71

    Google Scholar 

  160. 160

    Peng H, Poo M . Formation and dispersal of acetylcholine receptor clusters in muscle cells Trends Neurosci 1986; 9: 125–129

    CAS  Google Scholar 

  161. 161

    Maksymiw R, Sui SF, Gaub H, Sackmann E . Electrostatic coupling of spectrin dimers to phosphatidylserine containing lipid lamellae Biochemistry 1987; 26: 2983–2990

    CAS  PubMed  Google Scholar 

  162. 162

    Nelson W, Veshnock PJ . Ankyrin binding to (Na+ + K+) ATPase and implications for the organization of membrane domains in polarized cells Nature 1987; 328: 533–536

    CAS  PubMed  Google Scholar 

  163. 163

    Morgan RE, Palinkas LA, Barrett-Connor EL, Wingard DL . Plasma cholesterol and depressive symptoms in older men Lancet 1993; 341: 75–79

    CAS  PubMed  Google Scholar 

  164. 164

    Maes M, Smith R, Christophe A, Vandoolaeghe E, Van Gastel A, Neels H et al. Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers Acta Psychiatr Scand 1997; 95: 212–221

    CAS  PubMed  Google Scholar 

  165. 165

    Horsten M, Wamala SP, Vingerhoets A, Orth-Gomer K . Depressive symptoms, social support, and lipid profile in healthy middle-aged women Psychosom Med 1997; 59: 521–528

    CAS  PubMed  Google Scholar 

  166. 166

    Brown SL, Salive ME, Harris TB, Simonsick EM, Guralnik JM, Kohout FJ . Low cholesterol concentrations and severe depressive symptoms in elderly people BMJ 1994; 308: 1328–1332

    CAS  PubMed  PubMed Central  Google Scholar 

  167. 167

    Olusi SO, Fido AA . Serum lipid concentrations in patients with major depressive disorder Biol Psychiatry 1996; 40: 1128–1131

    CAS  PubMed  Google Scholar 

  168. 168

    Maes M, Jacobs MP, Suy E, Vandewoude M, Minner B, Raus J . Effects of dexamethasone on the availability of L-tryptophan and on the insulin and FFA concentrations in unipolar depressed patients Biol Psychiatry 1990; 27: 854–862

    CAS  PubMed  Google Scholar 

  169. 169

    Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H . Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids J Affect Disord 1996; 38: 35–46

    CAS  PubMed  Google Scholar 

  170. 170

    Peet M, Murphy B, Shay J, Horrobin D . Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients Biol Psychiatry 1998; 43: 315–319

    CAS  PubMed  Google Scholar 

  171. 171

    Edwards R, Peet M, Shay J, Horrobin D . Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients J Affect Disord 1998; 48: 149–155

    CAS  PubMed  Google Scholar 

  172. 172

    Bohus M, Forstner U, Kiefer C, Gebicke-Harter P, Timmer J, Spraul G et al. Increased sensitivity of the inositol-phospholipid system in neutrophils from patients with acute major depressive episodes Psychiatry Res 1996; 65: 45–51

    CAS  PubMed  Google Scholar 

  173. 173

    Smythies JR, Alarcon RD, Morere D, Monti JA, Steele M, Tolbert LC et al. Abnormalities of one-carbon metabolism in psychiatric disorders: study of methionine adenosyltransferase kinetics and lipid composition of erythrocyte membranes Biol Psychiatry 1986; 21: 1391–1398

    CAS  PubMed  Google Scholar 

  174. 174

    Tempesta E, Casella L, Pirrongelli C, Janiri L, Calvani M, Ancona L . L-Acetyl carnitine in depressed elderly subjects. A cross-over study vs placebo Drugs Exp Clin Res 1987; 13: 417–423

    CAS  PubMed  Google Scholar 

  175. 175

    Villardita C, Smirni P, Vecchio I . Acetyl-L-carnitine in depressed geriatric patients Eur Rev Med Pharm Sci 1983; 6: 1–12

    Google Scholar 

  176. 176

    De Simone C, Catania S, Trinchieri V, Tzantzoglou S, Calvani M, Bagiella E . Amelioration of the depression of HIV-infected subjects with L-acetyl carnitine therapy J Drug Dev 1988; 1: 163–166

    Google Scholar 

  177. 177

    Nasca D, Zurria G, Aguglia E . Action of acetyl-L-carnitine in association with mianserine on depressed old people New Trends Clin Neuropharmacol 1989; 3: 225–230

    Google Scholar 

  178. 178

    Bella R, Bondi R, Raffaele R, Pennisi G . Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders Int J Clin Pharmacol Res 1990; 10: 355–360

    CAS  PubMed  Google Scholar 

  179. 179

    Fulgente T, Onofrj M, Del Re ML, Ferracci F, Bazzano S, Ghilardi MF et al. Laevo-acetylcarnitine (NicetileR) treatment of senile depression Clin Tri J 1990; 27: 155–163

    Google Scholar 

  180. 180

    Garzya G, Corallo D, Fiore A, Lecciso G, Petrelli G, Zotti C . Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression Drugs Exp Clin Res 1990; 16: 101–106

    CAS  PubMed  Google Scholar 

  181. 181

    Gecele M, Francesetti G, Meluzzi A . Acetyl-L-carnitine in aged subjects with major depression: clinical efficacy and effects on the circadian rhythm of cortisol Dementia 1991; 2: 333–337

    Google Scholar 

  182. 182

    Reynolds CF, Frank E, Kupfer DJ, Thase ME, Perel JM, Mazumdar S et al. Treatment outcome in recurrent major depression: a post-hoc comparison of elderly (‘young old’) and mid-life patients Am J Psychiatry 1996; 153: 1288–1292

    PubMed  Google Scholar 

  183. 183

    Koran LM, Hamilton SH, Hertzman M, Meyers BS, Halaris AE, Tollefson GD et al. Predicting response to fluoxetine in geriatric patients with major depression J Clin Psychopharmacol 1995; 15: 421–427

    CAS  PubMed  Google Scholar 

  184. 184

    Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O et al. Double-blind, controlled trial of inositol treatment of depression Am J Psychiatry 1995; 152: 792–794

    CAS  PubMed  Google Scholar 

  185. 185

    Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial Arch Gen Psychiatry 1999; 56: 407–412

    CAS  PubMed  Google Scholar 

  186. 186

    Goodwin FK, Jamison KR . The manic-depressive spectrum Manic-Depressive Illness Oxford University Press: New York 1990; pp 74–85

    Google Scholar 

  187. 187

    Hayashi E, Maeda T, Tomita T . The effect of myo-inositol deficiency on lipid metabolism in rats. II. The mechanism of triacylglycerol accumulation in the liver of myo-inositol-deficient rats Biochim Biophys Acta 1974; 360: 146–155

    CAS  PubMed  Google Scholar 

  188. 188

    Pettegrew JW, Panchalingam K, Levine J, McClure RJ, Gershon S, Yao JK . Chronic myo–inositol increases rat brain phosphatidylethanolamine plasmalogen Biol Psychiatry 2000; 48: (in press)

  189. 189

    Glaser PE, Gross RW . Plasmenylethanolamine facilitates rapid membrane fusion: a stopped-flow kinetic investigation correlating the propensity of a major plasma membrane constituent to adopt an HII phase with its ability to promote membrane fusion Biochemistry 1994; 33: 5805–5812

    CAS  PubMed  Google Scholar 

  190. 190

    Nakamura J, Koh N, Sakakibara F, Hamada Y, Hara T, Sasaki H et al. Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats J Pharmacol Exp Ther 1998; 287: 897–902

    CAS  PubMed  Google Scholar 

  191. 191

    Stevens MJ, Lattimer SA, Feldman EL, Helton ED, Millington DS, Sima AA et al. Acetyl-L-carnitine deficiency as a cause of altered nerve myo-inositol content, Na,K- ATPase activity, and motor conduction velocity in the streptozotocin-diabetic rat Metabolism 1996; 45: 865–872

    CAS  PubMed  Google Scholar 

  192. 192

    Renshaw PF, Summers JJ, Renshaw CE . Changes in the 31P NMR spectra of cats receiving lithium chloride systemically Biol Psychiatry 1986; 21: 691–694

    Google Scholar 

  193. 193

    Joseph N, Renshaw P, Leigh J . Systemic lithium administration alters rat cerebral cortex phospholipids Biol Psychiatry 1987; 22: 540–544

    CAS  PubMed  Google Scholar 

  194. 194

    Jope RS . Effects of lithium treatment in vitro and in vivo on acetylcholine metabolism in rat brain J Neurochem 1979; 33: 487–495

    CAS  PubMed  Google Scholar 

  195. 195

    Sherman WR, Leavitt AL, Honchar MP, Hallcher LM, Phillips BE . Evidence that lithium alters phosphoinositide metabolism: chronic administration elevates primarily D-myo-inositol-1-phosphate in cerebral cortex of the rat J Neurochem 1981; 36: 1947–1951

    CAS  PubMed  Google Scholar 

  196. 196

    Berridge MJ, Downes CP, Hanley MR . Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands Biochem J 1982; 206: 587–595

    CAS  PubMed  PubMed Central  Google Scholar 

  197. 197

    Curti D, Dagani F, Galmozzi MR, Marzatico F . Effect of aging and acetyl-L-carnitine on energetic and cholinergic metabolism in rat brain regions Mech Ageing Dev 1989; 47: 39–45

    CAS  PubMed  Google Scholar 

  198. 198

    Davis S, Markowska AL, Wenk GL, Barnes CA . Acetyl-L-carnitine: behavioral, electrophysiological, and neurochemical effects Neurobiol Aging 1993; 14: 107–115

    CAS  PubMed  Google Scholar 

  199. 199

    Chang MC, Jones CR . Chronic lithium treatment decreases brain phospholipase A2 activity Neurochem Res 1998; 23: 887–892

    CAS  PubMed  Google Scholar 

  200. 200

    Friedman E . Lithium's effects on cyclic AMP, membrane transport and cholinergic mechanisms. In: Greshon S, Shopsin B (eds) Lithium: Its Role in Psychiatric Research and Treatments Plenum Press: New York 1973; 203–208

    Google Scholar 

  201. 201

    Forn J . Lithium and cyclic AMP. In: Johnson FN (ed) Lithium Research and Therapy Academic Press: New York 1975; pp 485–497

    Google Scholar 

  202. 202

    Avissar S, Schreiber G, Danon A, Belmarker RH . Lithium inhibits adrenergic and cholinergic increased in GTP binding in rat cortex Nature 1988; 331: 440–442

    CAS  PubMed  Google Scholar 

  203. 203

    Volonter C, Racker E . Lithium stimulation of membrane-bound phospholipase C from C12 cells exposed to nerve growth factor J Neurochem 1988; 51: 1163–1168

    Google Scholar 

Download references

Author information



Corresponding author

Correspondence to J W Pettegrew.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Pettegrew, J., Levine, J. & McClure, R. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol Psychiatry 5, 616–632 (2000).

Download citation


  • Alzheimer's disease
  • geriatric depression
  • acetyl-L-carnitine
  • lipid metabolism
  • energy metabolism
  • membrane
  • acetylation

Further reading


Quick links